WO2018045110A1 - Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors - Google Patents
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors Download PDFInfo
- Publication number
- WO2018045110A1 WO2018045110A1 PCT/US2017/049497 US2017049497W WO2018045110A1 WO 2018045110 A1 WO2018045110 A1 WO 2018045110A1 US 2017049497 W US2017049497 W US 2017049497W WO 2018045110 A1 WO2018045110 A1 WO 2018045110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- icos
- domain
- scfv
- variants
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- Tumor-reactive T cells lose their cytotoxic ability over time due to up-regulation of inhibitory immune checkpoints such as PD-1 and CTLA-4.
- Two parallel therapeutic strategies are being pursued for de-repressing tumor-reactive T cells so that they can continue to kill tumor cells.
- the first approach is immune immunomodulatory blockade by treating with antagonistic monoclonal antibodies that bind to either the immunomodulatory itself (PD-1, CTLA-4, etc.) or its ligand (PD-L1, PD-L2, CD80, CD86, etc.), thus removing the inhibitory signals holding back tumor-reactive T cells from tumor cell killing.
- Immunomodulatory receptors such as CTLA-1, PD-1 (programmed cell death 1), TIM-3 (T cell immunoglobulin and mucin domain 3), LAG-3 (lymphocyte-activation gene 3), TIGIT (T cell immunoreceptor with Ig and ITIM domains), and others, inhibit the activation, proliferation, and/or effector activities of T cells and other cell types.
- CTLA-1, PD-1 programmeed cell death 1
- TIM-3 T cell immunoglobulin and mucin domain 3
- LAG-3 lymphocyte-activation gene 3
- TIGIT T cell immunoreceptor with Ig and ITIM domains
- pembrolizumab, ipilimumab, and tremelimumab have indeed demonstrated that immunomodulatory blockade results in impressive anti-tumor responses, stimulating endogenous T cells to attack tumor cells, leading to long-term cancer remissions in a fraction of patients with a variety of malignancies.
- immunomodulatory blockade results in impressive anti-tumor responses, stimulating endogenous T cells to attack tumor cells, leading to long-term cancer remissions in a fraction of patients with a variety of malignancies.
- response rates generally ranging from 10 to 30% and sometimes higher for each monotherapy, depending on the indication and other factors.
- the second approach for de-repressing tumor-reactive T cells is T cell costimulation by treating with agonistic antibodies that bind to costimulatory proteins such as ICOS, thus adding a positive signal to overcome the negative signaling of the immune checkpoints.
- the invention is directed to bispecific antibodies that bind to costimulatory receptors (e.g. ICOS, GITR, OX40, 4-1BB) as well as checkpoint receptors (e.g. PD-1, PD-Ll, CTLA-4, LAG-3, TIM-3, BTLA and TIGIT.
- costimulatory receptors e.g. ICOS, GITR, OX40, 4-1BB
- checkpoint receptors e.g. PD-1, PD-Ll, CTLA-4, LAG-3, TIM-3, BTLA and TIGIT.
- the invention provides bispecific antibodies that monovalently binds a human costimulatory receptor and monovalently binds a human checkpoint receptor for use in activating T cells for the treatment of cancer.
- the costimulatory receptor is selected from the group consisting of ICOS, GITR, OX40 and 4-1BB.
- the checkpoint receptor is selected from the group consisting of PD-1, PD-Ll, CTLA-4, LAG-3, TIGIT and TIM-3.
- the antibody binds an antigen pair selected from: ICOS and PD-1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-Ll, ICOS and BTLA, ICOS and TIGIT, GITR and TIGIT, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-Ll, GITR and BTLA, OX40 and PD-1, OX40 and TIGIT, OX40 and CTLA-4, IC OX40 OS and LAG-3, OX40 and TIM-3, OX40 and PD-Ll, OX40 and BTLA, 4-1BB and PD-1, 4-1BB and CTLA-4, 4-1BB and LAG-3, 4-1BB and TIM-3, 4-1BB and PD-Ll, TIGIT and 4-1BB and 4-1BB and BTLA.
- an antigen pair selected
- the bispecific antibody has a format selected from those outlined in Figure 2.
- the invention provides heterodimeric antibodies comprising: a) a first heavy chain comprising a first Fc domain, an optional domain linker and a first antigen binding domain comprising an scFv that binds a first antigen; b) a second heavy chain comprising a heavy chain comprising a heavy chain constant domain comprising a second Fc domain, a hinge domain, a CHI domain and a variable heavy domain; and c) a light chain comprising a variable light domain and a light chain constant domain; wherein said variable heavy domain and said variable light domain form a second antigen binding domain that binds a second antigen, wherein one of said first and second antigen binding domains binds human ICOS and the other binds human PD-1.
- the invention provides heterodimeric bispecific antibodies comprising: a) a first heavy chain comprising: i) a first variant Fc domain; and ii) a single chain Fv region (scFv) that binds a first antigen, wherein said scFv region comprises a first variable heavy chain, a variable light chain and a charged scFv linker, wherein said charged scFv linker covalently attaches said first variable heavy chain and said variable light chain; and b) a second heavy chain comprising a VH-CHl-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy chain and CH2-CH3 is a second variant Fc domain; and c) a light chain; wherein said second variant Fc domain comprises amino acid substitutions
- first and second variant Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K; and wherein said first variant Fc domain comprises amino acid substitutions S364K/E357Q and second variant Fc domain comprises amino acid substitutions L368D/K370S, wherein one of said first and second antigen binding domains binds human ICOS and the other binds human PD-1, and wherein numbering is according to the EU index as in Kabat.
- heterodimeric antibodies have first and second variant Fc domains that each comprise M428L/N434S.
- the invention provides heterodimeric antibodies
- a first heavy chain comprising: i) a first variant Fc domain; and ii) a single chain Fv region (scFv) that binds a first antigen, wherein said scFv region comprises a first variable heavy chain, a variable light chain and a charged scFv linker, wherein said charged scFv linker covalently attaches said first variable heavy chain and said variable light chain; and b) a second heavy chain comprising a VH-CHl-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy chain and CH2-CH3 is a second variant Fc domain; and c) a light chain; wherein said first and second variant Fc domains comprises a set of
- heterodimerization variants selected from the group consisting of L368D/ 370S :
- the invention provides nucleic acid compositions comprising nucleic acids that encode the heterodimeric antibodies of the invention, expression vector compositions comprising the nucleic acids, and host cells comprising the expression vector compositions.
- the invention provides heterodimeric antibodies for use in the activation of T cells for the treatment of cancer.
- Figure 1 presents expression data (RNAseq V2 RSEM) of PD-1 and T cell costimulatory receptors for bladder, breast, colon, head & neck, kidney, lung-adeno, lung squamous, ovarian, pancreatic, prostate, and melanoma cancer compiled from The Cancer Genome Atlas (TCGA). The square of the Pearson correlation coefficient was calculated for PD-1 against T cell costimulatory receptors.
- Figure 2 A to O depict several formats for the bispecific antibodies of the present invention.
- the first is the "bottle opener” format, with a first and a second anti-antigen binding domain.
- mAb-Fv, mAb-scFv, Central-scFv, Central-Fv, one armed central-scFv, one scFv-mAb, scFv-mAb dual scFv format are all shown.
- Figure 2J depicts the "central-scFv2" format, with two Fab-scFv arms, wherein the Fabs bind a first antigen and the scFvs bind a second antigen.
- Figure 2K depicts the bispecific mAb format, with a first Fab arm binding a first antigen and a second Fab arm binding a second antigen.
- Figure 2L depicts the DVD-IgG format (see, e.g., U.S. Patent No. 7,612,181, hereby expressly incorporated by reference and as discussed below).
- Figure 2M depicts the Trident format (see, e.g., WO 2015/184203, hereby expressly incorporated by reference and as discussed below).
- the scFv domains depicted they can be either N- to C- terminus variable heavy-(optional linker)-variable light, or the opposite.
- the scFv can be attached either to the N-terminus of a heavy chain monomer or to the N-terminus of the light chain.
- Figure 3 depicts the sequences of XENP23104, a bottle opener format with the ICOS as the Fab side ([ICOS]_H0.66_L0) and the PD-1 as the scFv (1G6_L1.94_H1.279), and includes the M428L/434S variant to extend serum half life.
- the scFv linker is double underlined (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker, although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C- terminus; some of the sequences herein are oriented as VH-SCFV linker- VL (from N- to C- terminus), while some are oriented as VL-SCFV linker- VH (from N- to C-terminus), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- Figure 4A to E depict useful pairs of heterodimerization variant sets (including skew and pi variants).
- Figure 4C and F there are variants for which there are no
- corresponding "monomer 2" variants are pi variants which can be used alone on either monomer, or included on the Fab side of a bottle opener, for example, and an appropriate charged scFv linker can be used on the second monomer that utilizes a scFv as the second antigen binding domain.
- Suitable charged linkers are shown in Figure 8.
- Figure 5 depict a list of isosteric variant antibody constant regions and their respective substitutions.
- pl_(-) indicates lower pi variants, while pl_(+) indicates higher pi variants.
- pl_(+) indicates higher pi variants.
- Figure 6 depict useful ablation variants that ablate FcyR binding (sometimes referred to as “knock outs” or “KO” variants). Generally, ablation variants are found on both monomers, although in some cases they may be on only one monomer.
- Figure 7 show two particularly useful embodiments of the invention.
- the "non-Fv" components of this embodiment is shown in Figure 9 A, although the other formats of Figure 9 can be used as well.
- Figure 8A and B depict a number of charged scFv linkers that find use in increasing or decreasing the pi of heterodimeric antibodies that utilize one or more scFv as a component.
- the (+H) positive linker finds particular use herein.
- a single prior art scFv linker with single charge is references as "Whitlow", from Whitlow et al., Protein
- Figure 9 shows the sequences of several useful bottle opener format backbones based on human IgGl, without the Fv sequences (e.g. the scFv and the vh and vl for the Fab side).
- Bottle opener backbone 1 is based on human IgGl (356E/358M allotype), and includes the S364K E357Q : L368D/K370S skew variants, the N208D/Q295E/ 384D/Q418E/N421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 2 is based on human IgGl (356E/358M allotype), and includes different skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 3 is based on human IgGl (356E/358M allotype), and includes different skew variants, the N208D/Q295E/ 384D/Q418E/N421D pi variants on the Fab side and the E233P L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 4 is based on human IgGl (356E/358M allotype), and includes different skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 5 is based on human IgGl (356D/358L allotype), and includes the S364K/E357Q : L368D/ 370S skew variants, the N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 6 is based on human IgGl (356E/358M allotype), and includes the
- Bottle opener backbone 7 is identical to 6 except the mutation is N297S.
- Alternative formats for bottle opener backbones 6 and 7 can exclude the ablation variants E233P L234V/L235A/G236del/S267K in both chains.
- Backbone 8 is based on human IgG4, and includes the S364K/E357Q : L368D/K370S skew variants, the N208D/Q295E/ 384D/Q418E/N421D pi variants on the Fab side and the
- Alternative formats for bottle opener backbone 8 can exclude the ablation variants E233P/L234V L235A/G236del/S267K in both chains
- Backbone 9 is based on human IgG2, and includes the S364K E357Q : L368D/K370S skew variants, the
- Backbone 10 is based on human IgG2, and includes the S364K E357Q : L368D/K370S skew variants, the
- any Fv sequences outlined herein for anti-CTLA-4, anti-PD-1, anti- LAG-3, anti-TIM-3, anti-TIGIT and anti-BTLA, whether as scFv (again, optionally with charged scFv linkers) or as Fabs, can be incorporated into these Figure 37 backbones in any combination.
- the constant light chain depicted in Figure 9A can be used for all of the constructs in the figure, although the kappa constant light chain can also be substituted.
- bottle opener backbones find use in the Central-scFv format of Figure IF, where an additional, second Fab (vh-CHl and vl-constant light) with the same antigen binding as the first Fab is added to the N-terminus of the scFv on the "bottle opener side".
- each of these backbones includes sequences that are 90, 95, 98 and 99% identical (as defined herein) to the recited sequences, and/or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the "parent" of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgGl (or IgG2 or IgG4, depending on the backbone). That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition to the skew, pi and ablation variants contained within the backbones of this figure.
- Figure 10 depicts the sequences for a select number of anti-PD-1 antibodies. It is important to note that these sequences were generated based on human IgGl, with an ablation variant (E233P/L234V L235A/G236del/S267K, "IgGl_PVA JS267K") which is depicted in Figure 6A.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 11 depict a select number of PD-1 ABDs, with additional anti-PD-1 ABDs being listed as SEQ 1-2392, 3125-3144, 4697-7594 and 4697-21810.
- the CDRs are underlined, the scFv linker is double underlines (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C- terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus), while some are oriented as VL-scFv linker- VH (from N- to C-terminus), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- Figure 12 depict a select number of CTLA-4 ABDs, with additional anti-CTLA-4 ABDs being listed as SEQ ID NO:2393-2414 and 3737-3816.
- the CDRs are underlined, the scFv linker is double underlines (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C- terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus), while some are oriented as VL-scFv linker- VH (from N- to C-terminus), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- Figure 13 depict a select number of LAG-3 ABDs, with additional anti-LAG-3 ABDs being listed as SEQ ID NO:2415-2604 and 3817-3960.
- the CDRs are underlined, the scFv linker is double underlines (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker (SEQ ID NO: XXX), although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains>
- the naming convention illustrates the orientation of the scFv from N- to C-terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus), while some are oriented as VL-scFv linker- VH (from N
- Figure 14 depicts the sequences for a select number of anti-TIM-3 antibodies. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P/L234V L235A/G236del/S267K, "IgGl_PVA JS267K”) although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 15 depicts the sequences for a select number of anti-PD-Ll antibodies. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P L234V/L235A/G236del/S267K, "IgGl_PVA JS267K”) as outlined herein, although other formats can be used as well.
- the CDRs are underlined.
- Figure 16 depicts the sequences for a prototype anti-4-lBB antibody. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P/L234V L235A/G236del/S267K, "IgGl_PVA JS267K”), although the other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 17 depicts the sequences for a prototype anti-OX40 antibody. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P/L234V/L235A/G236del/S267K, "IgGl_PVA JS267K"), although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 18 depicts the sequences for a prototype anti-GITR antibody. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P/L234V/L235A/G236del/S267K, "IgGl_PVA JS267K”), although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 19 depicts the sequences for prototype anti-ICOS antibodies. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P/L234V/L235A/G236del/S267K, "IgGl_PVA JS267K”), although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table X, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 20 depicts sequences for exemplary anti-ICOS Fabs.
- the CDRs are underlined and slashes (/) indicate the border(s) of the variable regions.
- the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table X, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- these VH and VL sequences can be used either in a scFv format or in a Fab format. It is important to note that these sequences were generated using six- histidine (His6 or HHHHHH) C-terminal tags at the C-terminus of the heavy chains, which have been removed.
- Figure 21 depicts melting temperatures (Tm) and changes in melting temperature from the parental Fab (XENP22050) as determined by DSF of variant anti-ICOS Fabs engineered for stability.
- Figure 22 depicts equilibrium dissociation constants (KD), association rates (ka), and dissociation rates (kd) of variant anti-ICOS Fabs for murine Fc fusions of human ICOS captured on AMC biosensors as determined by Octet.
- Figure 23 depicts equilibrium dissociation constants (KD), association rates (ka), and dissociation rates (kd) of variant anti-ICOS Fabs for biotinylated IgGl Fc fusions of human ICOS captured on SA biosensors as determined by Octet.
- Figure 24 depicts sequences for exemplary anti-ICOS scFvs.
- the CDRs are underlined, the scFv linker is double underline (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker, although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure X), and slashes (/) indicate the border(s) of the variable regions.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C- terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus, see Figure 24), while some are oriented as VL-scFv linker-VH (from N- to C- terminus, see Figure 24B), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- VH and VL sequences can be used either in a scFv format or in a Fab format. It is important to note that these sequences were generated using polyhistidine (His6 or HHHHHH) C-terminal tags at the C-terminus of the heavy chains, which have been removed.
- Figure 25 depicts melting temperatures (Tm) and changes in melting temperature from the parental scFv (XENP24352; oriented as VH-scFv linker- VL from N- to C-terminus) as determined by DSF of variant anti-ICOS scFvs engineered for stability.
- Figure 26 depicts the amino acid sequences of prototype anti-costim x anti- checkpoint antibodies in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-SCFV linker- VL or VL-SCFV linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 27 depicts induction of cytokine secretion by prototype costim/checkpoint bottle-openers in an SEB-stimulated PBMC assay.
- Figure 28 depicts induction of IL-2 secretion in naive (non-SEB stimulated) and SEB- stimulated PBMCs following treatment with the indicated test articles.
- Figure 29 depicts a schematic associated with the benefit of a costim x checkpoint blockade bispecific antibody, showing that because tumor TILs co-express immune checkpoint receptors and costimulatory receptors, a bispecific antibody increases specificity, enhancing anti-tumor activity and avoiding peripheral toxicity.
- Figure 30 depicts that double-positive cells are selectively occupied by exemplary anti-ICOS x anti-PD-1 antibody (XENP20896) as compared to one-arm anti-PD-1 antibody (XENP20111) and one-arm anti-ICOS antibody (XENP20266).
- Figure 31 shows the receptor occupancy of anti-ICOS x anti-PD-1 bispecific antibody (XENP20896), one-arm anti-ICOS antibody (XENP20266) and one-arm anti-PD-1 antibody (XENP20111) on A) PD-1 and ICOS double-positive T cells and B) PD-1 and ICOS double- negative T cells after SEB stimulation of human PBMCs.
- Figure 32 depicts the amino acid sequences of exemplary anti-ICOS x anti-PD-1 antibodies in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-SCFV linker- VL or VL-SCFV linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 33 depicts the amino acid sequences of exemplary anti-ICOS x anti-PD-1 antibodies in the bottle-opener format (Fab-scFv-Fc) which include the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-SCFV linker- VL or VL-SCFV linker- VH as indicated, although this can be reversed.
- Figure 34 depicts equilibrium dissociation constants (KD), association rates (ka), and dissociation rates (kd) of variant anti-ICOS x anti-PD-1 bispecific antibodies for murine Fc fusion of human ICOS captured on AMC biosensors as determined by Octet.
- Figure 35 depicts equilibrium dissociation constants (KD), association rates (ka), and dissociation rates (kd) of variant anti-ICOS x anti-PD-1 bispecific antibodies for biotinylated IgGl Fc fusions of human and ICOS captured on SA/SAX biosensors as determined by Octet.
- Figure 36 depicts cell surface binding of variant anti-ICOS x anti-PD-1 bispecific to human T cells in SEB-stimulated PBMC assays in two separate experiments depicted in A) and B).
- Figure 37 shows the receptor occupancy of variant anti-ICOS x anti-PD-1 bispecific antibodies, one-arm anti-ICOS antibodies and one-arm anti-PD-1 antibody (XENP20111) on PD-1 and ICOS double-positive T cells after SEB stimulation of human PBMCs.
- Figure 38 show that variant anti-ICOS x anti-PD-1 bispecific antibodies promote A) IL-2 and B) IFNy secretion from SEB stimulated PBMCs.
- Figure 39 show that variant anti-ICOS x anti-PD-1 bispecific antibodies promote A) IL-2 and B) IFNy secretion from SEB-stimulated PBMCs.
- Figure 40 depicts the concentration of IFNy in mice on Day A) 7 and B) 11 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 41 depicts CD45+ cell counts in mice as determined by flow cytometry on Day A) 11 and B)14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 42 depicts A) CD8+ T cell and B) CD4+ T cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles (**p ⁇ 0.01).
- Figure 43 depicts the change in body weight in mice by Day 14 after engraftment with human PBMCs and treatment with the indicated test articles (**p ⁇ 0.01).
- Figure 44 depicts the concentration of IFNy in mice on Day A) 7 and B) 14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 45 depicts CD45+ cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 46 depicts A) CD8+ T cell and B) CD4+ T cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles.”
- Figure 47 depicts the change in body weight in mice by Day 12 and 15 after engraf tment with human PBMCs and treatment with the indicated test articles.
- Figure 48 depicts the amino acid sequences of exemplary anti-ICOS x anti-PD-1 antibodies in the bottle-opener format (Fab-scFv-Fc) with alternative ICOS ABDs.
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 49 depict cytokine release assay for IL-2 after SEB-stimulation of human PBMCs and treatment with alternative anti-ICOS x anti-PD-1 bispecific antibodies.
- Figure 50 depict cytokine release assay for IL-2 (as fold induction over bivalent anti- RSV mAb) after SEB-stimulation of human PBMCs and treatment with alternative anti-ICOS x anti-PD-1 bispecific antibodies.
- Figure 51 depicts AKT phosphorylation in SEB-stimulated purified CD3+ T cells after treatment with anti-ICOS x anti-PD-1 bispecific antibodies.
- Figure 52 depicts fold induction of A) IL-17A, B) IL17F, C) IL-22, D) IL-10, E) IL-9, and F) IFNy gene expression by the indicated test articles over induction by bivalent anti- RSV as determined by NanoString.
- Figure 53 depict mean fold induction in expression of selected immune response genes by indicated test articles over treatment with bivalent anti-RSV mAb as determined by NanoString.
- the shading intensity corresponds to the magnitude of the fold change.
- Figure 54 depicts CD45+ cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 55 depicts the sequences of the "backbone" portion (e.g. without the Fvs) of a number of additional formats, including the Central scFv of Figure 2F, the Central-scFv2 format of Figure 2J, the bispecific mAb of Figure 2K, the DVD-Ig of Figure 2L and the Trident format of Figure 2M.
- the DVD-Ig® linkers are shown with double underlining, with other linkers found in WO2007/024715, hereby incorporated by reference in its entirety and in particular for those sequences.
- Trident linkers and coil-coil sequences are shown in WO 2015/184203, hereby incorporated by reference in its entirety and in particular for those sequences.
- bolded domains e.g. "VH1”, VH2-scFv linker- VL2”, etc.
- slashes "/” may include optional domain linkers as needed.
- All of these backbones utilize the kappa constant region for the light chain, although the lambda chain can also be used.
- Figure 9 and Figure 75 these backbones can be combined with any vh and vl domains as outlined herein.
- Figure 56 depicts the amino acid sequence of illustrative anti-PD-1 x anti-ICOS antibodies in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 57 depicts the amino acid sequence of illustrative anti-PD-1 x anti-ICOS antibodies in the central-scFv format.
- the antibodies are named using the first Fab-Fc variable region first and the Fab-scFv-Fc variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, Fab-scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border (s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- FIG. 58 depicts the amino acid sequence of illustrative anti-PD-1 x anti-ICOS antibodies in the central-scFv2 format.
- the antibodies are named using the Fab variable region first and the scFv variable region second, followed by the chain designation (heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 59 depicts the amino acid sequence of an illustrative anti-PD-1 x anti-ICOS antibody in the bispecific mAb format.
- the antibodies are named using the first Fab variable region for a first antigen and the second Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain 1 or Light Chain 1 for the first antigen and Heavy Chain 2 or Light Chain 2 for the second antigen).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 60 depicts the amino acid sequence of an illustrative anti-PD-1 x anti-ICOS antibody in the DVD-IgG format.
- the antibodies are named using the first variable region for a first antigen and the second Fab variable region for a second antigen, followed by the chain designation (Heavy Chain or Light Chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 61 depicts the amino acid sequence of an illustrative anti-PD-1 x anti-ICOS antibody in the Trident format.
- the antibodies are named using the VL and VH of a first antigen which comprises a DART and the Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain or Light Chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 62 depicts induction of cytokine secretion (IL-2) by alternative format costim x checkpoint blockade bispecific antibodies in an SEB-stimulated PBMC assay.
- IL-2 cytokine secretion
- Figure 63 depicts the amino acid sequences of an illustrative anti-ICOS x anti-CTLA- 4 antibody in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 64 depicts the amino acid sequence of illustrative anti-LAG-3 x anti-ICOS antibodies in the bispecific mAb format.
- the antibodies are named using the first Fab variable region for a first antigen and the second Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain 1 or Light Chain 1 for the first antigen and Heavy Chain 2 or Light Chain 2 for the second antigen).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 65 depicts the amino acid sequence of an illustrative anti-TIM-3 x anti-ICOS antibody in the bispecific mAb format.
- the antibodies are named using the first Fab variable region for a first antigen and the second Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain 1 or Light Chain 1 for the first antigen and Heavy Chain 2 or Light Chain 2 for the second antigen).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 66 depicts the amino acid sequences of anti-ICOS x anti-PD-Ll antibodies in the bottle-opener format (Fab-scFv-Fc) and central-scFv2 format.
- the bottle-openers are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- Central-scFv2s are named using the Fab variable region first and the scFv variable region second, followed by the chain designation (heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 67 depicts induction of cytokine secretion (IL-2) by additional costim x checkpoint blockade bispecific antibodies in an SEB-stimulated PBMC assay.
- Figure 68 depict amino acid sequences for exemplary one-arm anti-ICOS Fab-Fc antibodies.
- CDRs are underlined and slashes indicate the border(s) of variable regions. These are referred to as "one-arm” or “one armed” formats as one amino acid chain is only an Fc domain, with the other side being an anti-ICOS Fab side.
- the Fc domain contains the S364K E357Q skew variants, as well as the pI(-)_Isosteric_A variants depicted in Figure X.
- the Fab Fc domain contains the L368D/K370S skew variants as well as the pi ISO(+RR) variants depicted in Figure X. Both Fc domains include the ablation variants
- Figure 69 depicts equilibrium dissociation constants (KD), association rates (ka), and dissociation rates (kd) of variant one-arm anti-ICOS Fab-Fc antibodies for murine Fc fusions of human ICOS captured on AMC biosensors as determined by Octet.
- Figure 70 depicts AKT phosphorylation in SEB-stimulated purified CD3+ T cells after treatment with bivalent and monovalent anti-PD-1 antibodies and anti-ICOS x anti-PD-1 bispecific antibodies.
- Figure 71 depicts AKT phosphorylation in purified CD3+ T cells after treatment with monovalent anti-ICOS Fab-Fc antibodies with alternative anti-ICOS ABDs.
- Figure 72 depict some prototype bispecific antibodies (OX40 X PD-1, GITR X PD-1, 4-1BB X PD-1, CTLA-4 X ICOS).
- Figure 73 depict some prototype mAbs (4-1BB, OX40, GITR, ICOS, PD-L1 and PD-1), the Fvs of which can be used in combination with the other Fvs of the invention and in any format (bottle opener, mAb-Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- Some additional ICOS X PD-L1 bottle opener sequences are shown as well.
- Figure 74 depict additional PD-1 X ICOS bottle openers, in some cases with the PD-1 Fv being in the Fab format and the ICOS Fv in a scFv format and in other cases reversed.
- Figure 75A to D shows the sequences of a mAb-scFv backbone of use in the invention, to which the Fv sequences of the invention are added.
- mAb-scFv backbone 1 is based on human IgGl (356E/358M allotype), and includes the S364K E357Q : L368D/K370S skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Backbone 2 is based on human IgGl (356D/358L allotype), and includes the S364K/E357Q : L368D/K370S skew variants, the N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Backbone 3 is based on human IgGl (356E/358M allotype), and includes the S364K E357Q : L368D/ 370S skew variants, N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side and the
- Backbone 4 is identical to 3 except the mutation is N297S.
- Backbone 5 is based on human IgG4, and includes the S364K/E357Q : L368D/K370S skew variants, the
- Backbone 6 is based on human IgG2, and includes the S364K E357Q : L368D/ 370S skew variants, the N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side.
- Backbone 7 is based on human IgG2, and includes the S364K/E357Q : L368D/ 370S skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side as well as a S267K variant on both chains.
- these sequences can be used with any vh and vl pairs outlined herein, with one monomer including both a Fab and an scFv (optionally including a charged scFv linker) and the other monomer including the Fab sequence (e.g. a vh attached to the "Fab side heavy chain” and a vl attached to the "constant light chain”).
- any Fv sequences outlined herein for anti-CTLA-4, anti-PD- 1, anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-BTLA, anti-ICOS, anti-GITR, anti-OX40 and anti- 4-1BB, whether as scFv (again, optionally with charged scFv linkers) or as Fabs, can be incorporated into this Figure 75 backbone in any combination.
- the monomer 1 side is the Fab-scFv pi negative side, and includes the heterodimerization variants L368D/ 370S, the isosteric pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants
- the monomer 2 side is the scFv pi positive side, and includes the heterodimerization variants 364K E357Q.
- other skew variant pairs can be substituted, particularly [S364K E357Q : L368D/ 370S];
- these mAb-scFv backbones find use in the both the mAb-Fv format of Figure 1H (where one monomer comprises a vl at the C-terminus and the other a vh at the C-terminus) as well as the scFv-mAb format (with a scFv domain added to the C- terminus of one of the monomers).
- each of these backbones includes sequences that are 90, 95, 98 and 99% identical (as defined herein) to the recited sequences, and/or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the "parent" of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgGl (or IgG2 or IgG4, depending on the backbone). That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition to the skew, pi and ablation variants contained within the backbones of this figure.
- Figure 76 depict a number of prior art sequences for Fvs that bind human PD-
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4-1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb-Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-lg or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4-1BB, including the Fv sequences contained herein
- Figure 77 depict a number of prior art sequences for Fvs that bind human
- ICOS as vh and vl sequences.
- any of these Fvs can be combined with an Fv that binds a checkpoint receptor (e.g. PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA, including the Fv sequences contained herein) and in any format (bottle opener, mAb-Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-lg or Trident).
- a checkpoint receptor e.g. PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA, including the Fv sequences contained herein
- mAb-Fv mAb-scFv
- central-scFv bispecific mAb
- central-Fv one armed central-s
- PD-1 ABDs having the identifiers 1G6_H1.279_L1.194; 1G6_H1.280_L1.224; 1G6_L1.194_H1.279; 1G6_L1.210_H1.288; and 2E9 H1L1.
- Figure 78 depict a number of prior art sequences for Fvs that bind human PD-
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4-1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb-Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-lg or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4-1BB, including the Fv sequences contained herein
- Figure 79 depict a number of prior art sequences for Fvs that bind human
- CTLA-4 as vh and vl sequences.
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb- Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein
- mAb- Fv mAb-scFv
- central-scFv bispecific mAb
- central-Fv one armed central-scFv
- one armed scFv-mAb dual scFv
- Figure 80 depict a number of prior art sequences for Fvs that bind human
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb- Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein
- Figure 81 depict a number of prior art sequences for Fvs that bind human
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb- Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein
- Figure 82 depict a number of prior art sequences for Fvs that bind human
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb- Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein
- Figure 83 depict a number of prior art sequences for Fvs that bind human
- any of these Fvs can be combined with an Fv that binds a costimulatory receptor (e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein) and in any format (bottle opener, mAb- Fv, mAb-scFv, central-scFv, bispecific mAb, central-Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- a costimulatory receptor e.g. ICOS, GITR, OX40 or 4- 1BB, including the Fv sequences contained herein
- Figure 84A to C depict a number of BTLA ABDs, with additional anti-BTLA
- ABDs being listed as SEQ ID NO: 3705-3736.
- the CDRs are underlined, the scFv linker is double underlined (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker, although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C-terminus; in the sequences listed in this figure, they are all oriented as vh-scFv linker-vl (from N- to C- terminus), although these sequences may also be used in the opposite orientation, (from N- to C-terminus) vl-linker-vh.
- the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the vh and vl domains using other numbering systems.
- these vh and vl sequences can be used either in a scFv format or in a Fab format.
- Figure 85 is a matrix of possible combinations of the costim and checkpoint
- ABD ABDs, with all possible combinations possible.
- An “A” in the box means that the PD-1 ABD is 1G6_L1.194_H1.279.
- a “B” in the box means that the ICOS ABD is [ICOS]H.066_L0.
- a “C” in the box means that the PD-1 is the scFv in the pair.
- a “D” in the box means the CTLA-4 ABD is a Fab and is [CTLA-4]_H3_L0.22.
- An “E” in the box means that the CTLA-4 ABD is a scFv and is [CTLA-4]_H3.23_L0.22.
- An “F” in the box means that the LAG-3 ABD is 7G8_H3.30_L1.34.
- a “G” in the box means that the BTLA ABD is 9C6_H1.1_L1.
- An “H” in the box means that combination is a bottle opener.
- Figure 86 depicts two more ICOS X PD-1 bottle openers.
- the bispecific antibodies of the invention are listed in several different formats. Each polypeptide is given a unique "XENP" number, although as will be appreciated in the art, a longer sequence might contain a shorter one. For example, the heavy chain of the scFv side monomer of a bottle opener format for a given sequence will have a first XENP number, while the scFv domain will have a different XENP number. Some molecules have three polypeptides, so the XENP number, with the components, is used as a name.
- the molecule XENP which is in bottle opener format, comprises three sequences, generally referred to as "XENP23104-HC-Fab", XENP23104 HC-scFv" and “XENP23104 LC” or equivalents, although one of skill in the art would be able to identify these easily through sequence alignment.
- These XENP numbers are in the sequence listing as well as identifiers, and used in the Figures.
- one molecule, comprising the three components, gives rise to multiple sequence identifiers.
- the listing of the Fab monomer has the full length sequence, the variable heavy sequence and the three CDRs of the variable heavy sequence;
- the light chain has a full length sequence, a variable light sequence and the three CDRs of the variable light sequence;
- the scFv-Fc domain has a full length sequence, an scFv sequence, a variable light sequence, 3 light CDRs, a scFv linker, a variable heavy sequence and 3 heavy CDRs; note that all molecules herein with a scFv domain use a single charged scFv linker (+H), although others can be used.
- variable domains uses a "Hx.xx_Ly.yy” type of format, with the numbers being unique identifiers to particular variable chain sequences.
- variable domain of the scFv side of XENP23104 (which binds PD-1) is "1G6_
- L1.194_H1.279 which indicates that the variable heavy domain H1.279 was combined with the light domain LI.194.
- the designation "1G6_ L1.194_H1.279” indicates that the variable heavy domain H1.279 was combined with the light domain LI.194 and is in vl-linker-vh orientation, from N- to C-terminus.
- This molecule with the identical sequences of the heavy and light variable domains but in the reverse order would be named "1G6_H1.279_L1.194”.
- different constructs may "mix and match" the heavy and light chains as will be evident from the sequence listing and the Figures.
- Target Antigens The sequence of human PD-1 (sp I Q15116) is SEQ ID NO:
- the sequence of human PD-1, extracellular domain is SEQ ID NO: 26227.
- the sequence of macaca fasdcularis PD-1 (tr I B0LAJ3) is SEQ ID NO: 26228.
- the sequence of macaca fasdcularis PD-1, extracellular domain (predicted) (tr I B0LAJ3 121-170) is SEQ ID NO: 26229.
- the sequence of human CTLA-4 (sp I P16410) is SEQ ID NO: 26230.
- the sequence of human CTLA-4, extracellular domain is SEQ ID NO: 26231.
- the sequence of macaca fasdcularis CTLA-4 (tr I G7PL88) is SEQ ID NO: 26232.
- the sequence of macaca fasdcularis CTLA-4, extracellular domain (predicted) (tr I G7PL88) is SEQ ID NO: 26233.
- the sequence of human LAG-3 (sp I P18627) is SEQ ID NO: 26234.
- the sequence of human LAG-3, extracellular domain (sp I P18627129-450) is SEQ ID NO: 26235.
- the sequence of macaca fasdcularis LAG-3 (predicted) (gi 1544467815 1 ref I XP_005570011.1) is SEQ ID NO: 26236.
- the sequence of macaca fasdcularis LAG-3, extracellular domain (predicted) (gi 1544467815 1 ref I XP_005570011.1 129-450) is SEQ ID NO: 26237.
- the sequence of human TIM-3 (sp I Q8TDQ0) is SEQ ID NO: 26238.
- the sequence of human TIM-3, extracellular domain (sp I Q8TDQ0 122-202) is SEQ ID NO: 26239.
- the sequence of macaca fasdcularis TIM-3 (predicted) (gi 1355750365 1 gb I EHH54703.1) is SEQ ID NO: 26240.
- the sequence of macaca fasdcularis PD-Ll, extracellular domain (predicted) (gb I XP_005581836.1 119-238) is SEQ ID NO: 26245.
- the sequence of human ICOS (sp I Q9Y6W8) is SEQ ID NO: 26246.
- the sequence of human ICOS, extracellular domain (sp I Q9Y6W8 121-140) is SEQ ID NO: 26247.
- the sequence of macaca fascicularis ICOS (gi 1544477053 1 ref I XP_005574075.1) is SEQ ID NO: 26248.
- the sequence of human GITR (sp I Q9Y5U5) is SEQ ID NO: 26250.
- the sequence of human GITR, extracellular domain (sp I Q9Y5U5 126-162) is SEQ ID NO: 26251.
- the sequence of macaca fascicularis GITR (predicted) (ref I XP_005545180.1) is SEQ ID NO: 26252.
- the sequence of macaca fascicularis GITR, extracellular domain (predicted) (ref I XP_005545180.1 126-162) is SEQ ID NO: 26253.
- the sequence of human OX40 (sp I P43489) is SEQ ID NO: 26254.
- the sequence of human OX40, extracellular domain is SEQ ID NO: 26255.
- the sequence of macaca fascicularis OX40 (predicted) (ref I XP_005545179.1) is SEQ ID NO: 26256.
- the sequence of macaca fascicularis OX40, extracellular domain (predicted)
- SEQ ID NO:27869-28086 contain a number of ICOS Fab sequences (heavy chain VH1-CH1 and light chain VL1-CL) as indicated in the naming nomenclature.
- SEQ ID NO:28549-28556 show some control antibodies (HC and LC) from which the Fvs can be used as ICOS ABDs as well; reference for the CDRs and for the junction between the variable junctions is shown in Figure 44 of USSN 62/479,723 (hereby incorporated by reference as well as the Legend), although from the SEQ listing one of skill in the art will be able to ascertain the CDRs (see Table 1 for numbering and/or through sequence alignment) as well as for the junctions (e.g. heavy chain CHI generally starts with the sequence "ASTK . . .” and light chain constant domain generally starts with "RTVA . . .”.
- SEQ ID NO:28557-28665 show some ICOS scFvs that find use in combination in the invention; reference for the CDRs and for the junction between the variable junctions is shown in Figure 45 of USSN 62/479,723 (hereby incorporated by reference as well as the Legend), although from the SEQ listing one of skill in the art will be able to ascertain the CDRs (see Table 1 for numbering and/or through sequence alignment) as well as for the junctions, as the scFvs utilize the charged linker (GKPGS)4 between the vh and vl domains.
- GKPGS charged linker
- ICOS ABDs for use in combination with ABDs for checkpoint receptors are shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193-27335, 28549-28556 and 28557-28665, and [ICOS]_H0.66_L0 and [ICOS]_H0_L0.
- suitable ICOS X PD-1 bottle opener sequences include those in
- Therapeutic antibodies directed against immune immunomodulatory inhibitors such as PD-1 are showing great promise in limited circumstances in the clinic for the treatment of cancer. Cancer can be considered as an inability of the patient to recognize and eliminate cancerous cells. In many instances, these transformed (e.g. cancerous) cells counteract immunosurveillance. There are natural control mechanisms that limit T-cell activation in the body to prevent unrestrained T-cell activity, which can be exploited by cancerous cells to evade or suppress the immune response. Restoring the capacity of immune effector cells-especially T cells-to recognize and eliminate cancer is the goal of immunotherapy.
- immuno-oncology sometimes referred to as "immunotherapy'' is rapidly evolving, with several recent approvals of T cell checkpoint inhibitory antibodies such as Yervoy, Keytruda and Opdivo. These antibodies are generally referred to as “checkpoint inhibitors” because they block normally negative regulators of T cell immunity. It is generally understood that a variety of immunomodulatory signals, both costimulatory and coinhibitory, can be used to orchestrate an optimal antigen-specific immune response.
- Checkpoint inhibitor monoclonal antibodies bind to immunomodulatory inhibitor proteins such as PD-1, which under normal circumstances prevent or suppress activation of cytotoxic T cells (CTLs).
- CTLs cytotoxic T cells
- By inhibiting the immunomodulatory protein for example through the use of antibodies that bind these proteins, an increased T cell response against tumors can be achieved. That is, these cancer immunomodulatory proteins suppress the immune response; when the proteins are blocked, for example using antibodies to the immunomodulatory protein, the immune system is activated, leading to immune stimulation, resulting in treatment of conditions such as cancer and infectious disease.
- ICOS Inducible T cell Co-Stimulator, also referred to as CD278
- CD278 co-stimulatory proteins
- ICOS is a type I transmembrane protein comprising an extracellular (Ig) V-like domain, and serves as the receptor for the B7h co-stimulatory molecule.
- TILs tumor infiltrating lymphocytes
- Bispecific antibodies which can bind two different targets simultaneously, offer the potential to improve the selectivity of targeting TILs vs peripheral T cells, while also reducing cost of therapy.
- the bivalent interaction of an antibody with two targets on a cell surface should - in some cases - lead to a higher binding avidity relative to a monovalent interaction with one target at a time. Because of this, normal bivalent antibodies tend to have high avidity for their target on a cell surface. With bispecific antibodies, the potential exists to create higher selectivity for cells that simultaneously express two different targets, utilizing the higher avidity afforded by simultaneous binding to both targets.
- the present invention provides bispecific immunomodulatory antibodies, that bind to cells expressing the two antigens and methods of activating T cells and/or NK cells to treat diseases such as cancer and infectious diseases, and other conditions where increased immune activity results in treatment.
- the invention is directed, in some instances, to solving the issue of toxicity and expense of administering multiple antibodies by providing bispecific antibodies that bind to two different immunomodulatory molecules (one a checkpoint receptor and the other a costimulatory receptor) on a single cell and advantageously requiring administration of only one therapeutic substance.
- immunomodulatory blockade with costimulation in one molecule it is not obvious what combination of immune immunomodulatory plus costimulatory protein or what binding stoichiometry (monovalent + monovalent, monovalent + bivalent, etc.) would be efficacious.
- bispecific antibodies that binding monovalently to a costimulatory protein (such as ICOS) and monovalent binding to a checkpoint receptor (such as PD-1) that are capable of inducing robust T cell activation.
- ICOS ligation induces AKT phosphorylation.
- the studies here in use AKT phosphorylation as an indicator of ICOS agonism, and this effect is seen for both "one armed ICOS" (see Example 5A(a)) and for bispecific antibodies that bind ICOS monovalently.
- the one-arm XENP20266 that only binds ICOS monovalently promotes more AKT phosphorylation than XENP16435, which binds ICOS bivalently (e.g. as a traditional mAb).
- the present invention is directed to novel constructs to provide heterodimeric, bispecific antibodies that allow binding to a checkpoint receptor as well as human ICOS.
- bispecific antibodies are named "anti-PD-1 X anti-
- the heterodimeric bispecific immunomodulatory antibodies of the invention are useful to treat a variety of types of cancers.
- immunomodulatory antibodies are used to increase the immune response but are not generally tumor specific in their action. That is, the bispecific immunomodulatory antibodies of the invention inhibit the suppression of the immune system, generally leading to T cell activation, which in turn leads to greater immune response to cancerous cells and thus treatment.
- T cell activation can be measured.
- Functional effects of the bispecific immunomodulatory antibodies on NK and T- cells can be assessed in vitro (and in some cases in vivo, as described more fully below) by measuring changes in the following parameters: proliferation, cytokine release and cell- surface makers.
- NK cells increases in cell proliferation, cytotoxicity (ability to kill target cells as measured by increases in CD107a, granzyme, and perforin expression, or by directly measuring target cells killing), cytokine production (e.g. IFN- ⁇ and TNF), and cell surface receptor expression (e.g. CD25) is indicative of immune modulation, e.g. enhanced killing of cancer cells.
- T-cells For T-cells, increases in proliferation, increases in expression of cell surface markers of activation (e.g. CD25, CD69, CD137, and PD1), cytotoxicity (ability to kill target cells), and cytokine production (e.g. IL-2, IL-4, IL-6, IFN, TNF-a, IL-10, IL-17A) are indicative of immune modulation, e.g. enhanced killing of cancer cells.
- cell surface markers of activation e.g. CD25, CD69, CD137, and PD1
- cytotoxicity ability to kill target cells
- cytokine production e.g. IL-2, IL-4, IL-6, IFN, TNF-a, IL-10, IL-17A
- assessment of treatment can be done using assays that evaluate one or more of the following: (i) increases in immune response, (ii) increases in activation of ⁇ and/or ⁇ T cells, (iii) increases in cytotoxic T cell activity, (iv) increases in NK and/or NKT cell activity, (v) alleviation of ⁇ and/or ⁇ T-cell suppression, (vi) increases in pro-inflammatory cytokine secretion, (vii) increases in IL-2 secretion; (viii) increases in interferon- ⁇ production, (ix) increases in Thl response, (x) decreases in Th2 response, (xi) decreases or eliminates cell number and/or activity of at least one of regulatory T cells, (xii) increases in IL-2 secretion.
- the invention provides the use of bispecific immunomodulatory antibodies to perform one or more of the following in a subject in need thereof: (a) upregulating pro-inflammatory cytokines; (b) increasing T-cell proliferation and/or expansion; (c) increasing interferon- ⁇ or TNF-a production by T-cells; (d) increasing IL-2 secretion; (e) stimulating antibody responses; (f) inhibiting cancer cell growth; (g) promoting antigenic specific T cell immunity; (h) promoting CD4+ and/or CD8+ T cell activation; (i) alleviating T-cell suppression; (j) promoting NK cell activity; (k) promoting apoptosis or lysis of cancer cells; and/or (1) cytotoxic or cytostatic effect on cancer cells.
- the present invention provides bispecific immunomodulatory antibodies.
- formats that can be used in the present invention, as generally shown in Figure 2, many of which are heterodimeric (although not all, as DVD-Ig, for example).
- heterodimeric antibodies constructs are based on the self-assembling nature of the two Fc domains of the heavy chains of antibodies, e.g. two "monomers” that assemble into a "dimer".
- Heterodimeric antibodies are made by altering the amino acid sequence of each monomer as more fully discussed below.
- the present invention is generally directed to the creation of heterodimeric antibodies, which can co-engage two antigens in several ways, relying on amino acid variants in the constant regions that are different on each chain to promote heterodimeric formation and/or allow for ease of purification of heterodimers over the homodimers.
- the present invention provides bispecific immunomodulatory antibodies.
- An ongoing problem in antibody technologies is the desire for "bispecific" antibodies that bind to two (or more) different antigens simultaneously, in general thus allowing the different antigens to be brought into proximity and resulting in new functionalities and new therapies.
- these antibodies are made by including genes for each heavy and light chain into the host cells (generally, in the present invention, genes for two heavy chain monomers and a light chain as outlined herein). This generally results in the formation of the desired heteroditner (A-B), as well as the two homodimers (A-A and B-B).
- a major obstacle in the formation of bispecific antibodies is the difficulty in purifying the heterodimeric antibodies away from the homodimeric antibodies and/or biasing the formation of the heteroditner over the formation of the homodimers.
- heterodimerization variants amino acid variants that lead to the production of heterodimeric antibodies are referred to as “heterodimerization variants”.
- heterodimerization variants can include steric variants (e.g. the "knobs and holes” or “skew” variants described below and the “charge pairs” variants described below) as well as “pi variants", which allows purification of homodimers away from heterodimers.
- T366S L368A/Y407V paired with T366W as well as this variant with a bridging disulfide
- T366S/L368A/Y407V/Y349C paired with T366W/S354C particularly in combination with other heterodimerization variants including pi variants as outlined below.
- electrostatic steering or “charge pairs” as described in Gunasekaran et al., J. Biol. Chem. 285(25):19637 (2010), hereby incorporated by reference in its entirety. This is sometimes referred to herein as “charge pairs”.
- electrostatics are used to skew the formation towards heterodimerization. As those in the art will appreciate, these may also have an effect on pi, and thus on purification, and thus could in some cases also be considered pi variants. However, as these were generated to force heterodimerization and were not used as purification tools, they are classified as "steric variants”.
- D221E/P228E/L368E paired with D221R/P228R/K409R e.g. these are "monomer corresponding sets
- pi variants are used to alter the pi of one or both of the monomers and thus allowing the isoelectric purification of A- A, A-B and B-B dimeric proteins.
- scaffolds that utilize scFv(s) such as the Triple F format can include charged scFv linkers (either positive or negative), that give a further pi boost for purification purposes.
- charged scFv linkers either positive or negative
- some Triple F formats are useful with just charged scFv linkers and no additional pi adjustments, although the invention does provide the use of skew variants with charged scFv linkers as well (and combinations of Fc, FcRn and KO variants discussed herein).
- amino acid variants can be introduced into one or both of the monomer polypeptides; that is, the pi of one of the monomers (referred to herein for simplicity as "monomer A”) can be engineered away from monomer B, or both monomer A and B change be changed, with the pi of monomer A increasing and the pi of monomer B decreasing.
- the pi changes of either or both monomers can be done by removing or adding a charged residue (e.g. a neutral amino acid is replaced by a positively or negatively charged amino acid residue, e.g.
- suitable pi variants for use in the creation of heterodimeric antibodies herein are those that are isotypic, e.g. importing pi variants from different IgG isotypes such that pi is changed without introducing significant immunogenicity; see Figure 29 from US Publication No. 20140288275, hereby incorporated by reference in its entirety.
- this embodiment of the present invention provides for creating a sufficient change in pi in at least one of the monomers such that heterodimers can be separated from homodimers.
- this can be done by using a "wild type" heavy chain constant region and a variant region that has been engineered to either increase or decrease its pi (wt A-+B or wt A - -B), or by increasing one region and decreasing the other region (A+ -B- or A- B+).
- a component of some embodiments of the present invention are amino acid variants in the constant regions of antibodies that are directed to altering the isoelectric point (pi) of at least one, if not both, of the monomers of a dimeric protein to form "pi heterodimers" (when the protein is an antibody, these are referred to as “pi antibodies") by incorporating amino acid substitutions ("pi variants" or "pi substitutions") into one or both of the monomers.
- the separation of the heterodimers from the two homodimers can be accomplished if the pis of the two monomers differ by as little as 0.1 pH unit, with 0.2, 0.3, 0.4 and 0.5 or greater all finding use in the present invention.
- the number of pi variants to be included on each or both monomer(s) to get good separation will depend in part on the starting pi of the scFv and Fab of interest. That is, to determine which monomer to engineer or in which "direction" (e.g. more positive or more negative), the Fv sequences of the two target antigens are calculated and a decision is made from there. As is known in the art, different Fvs will have different starting pis which are exploited in the present invention. In general, as outlined herein, the pis are engineered to result in a total pi difference of each monomer of at least about 0.1 logs, with 0.2 to 0.5 being preferred as outlined herein.
- heterodimers can be separated from homodimers on the basis of size (e.g. Molecular weight).
- size e.g. Molecular weight
- some formats result in homodimers and heterodimers with different sizes (e.g. for bottle openers, one homodimer is a "dual scFv" format, one homodimer is a standard antibody, and the heterodimer has one Fab and one scFv).
- heterodimerization variants including skew and purification heterodimerization variants
- the possibility of immunogenicity resulting from the pi variants is significantly reduced by importing pi variants from different IgG isotypes such that pi is changed without introducing significant immunogenicity.
- an additional problem to be solved is the elucidation of low pi constant domains with high human sequence content, e.g. the miriimization or avoidance of non-human residues at any particular position.
- a side benefit that can occur with this pi engineering is also the extension of serum half-life and increased FcRn binding. That is, as described in USSN 13/194,904 (incorporated by reference in its entirety), lowering the pi of antibody constant domains (including those found in antibodies and Fc fusions) can lead to longer serum retention in vivo. These pi variants for increased serum half life also facilitate pi changes for purification.
- the pi variants of the heterodimerization variants give an additional benefit for the analytics and quality control process of bispecific antibodies, as the ability to either eliminate, minimize and distinguish when homodimers are present is significant. Similarly, the ability to reliably test the reproducibility of the heterodimeric protein production is important.
- First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively, wth one being a costimulatory receptor and one being a checkpoint receptor.
- One heterodimeric scaffold that finds particular use in the present invention is the "triple f" or "bottle opener” scaffold format.
- one heavy chain of the antibody contains an single chain fv ("scfv", as defined below) and the other heavy chain is a "regular" fab format, comprising a variable heavy chain and a light chain.
- This structure is sometimes referred to herein as “triple f” format (scfv-fab-f c) or the “bottle- opener” format, due to a rough visual similarity to a bottle-opener (see Figure 2).
- the two chains are brought together by the use of amino acid variants in the constant regions (e.g. the Fc domain and/or the hinge region) that promote the formation of heterodimeric antibodies as is described more fully below.
- additional amino acid variants may be introduced into the bispecific antibodies of the invention, to add additional functionalities.
- amino acid changes within the Fc region can be added (either to one monomer or both) to facilitate increased ADCC or CDC (e.g. altered binding to Fey receptors) as well as to increase binding to FcRn and/or increase serum half-life of the resulting molecules.
- ADCC or CDC e.g. altered binding to Fey receptors
- any and all of the variants outlined herein can be optionally and independently combined with other variants.
- Fey ablation variants or “Fc knock out (FcKO or KO) variants.
- FcKO or KO Fey ablation variants
- Suitable ablation variants are shown in Figure 6.
- ablation herein is meant a decrease or removal of activity.
- “ablating FcyR binding” means the Fc region amino acid variant has less than 50% starting binding as compared to an Fc region not containing the specific variant, with less than 70-80-90-95-98% loss of activity being preferred, and in general, with the activity being below the level of detectable binding in a Biacore assay.
- ablation FcyR binding are those shown in Figure 6.
- ADCC antibody dependent cell-mediated cytotoxicity
- ADCP antibody dependent cell-mediated phagocytosis as used herein is meant the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcyRs recognize bound antibody on a target cell and subsequently cause phagocytosis of the target cell.
- antigen binding domain or "ABD” herein is meant a set of six
- CDRs Complementary Determining Regions
- immunomodulatoryantigen binding domain binds a target immunomodulatoryantigen as outlined herein.
- these CDRs are generally present as a first set of variable heavy CDRs (vhCDRs or VHCDRS) and a second set of variable light CDRs (vlCDRs or VLCDRS), each comprising three CDRs: vhCDRl, vhCDR2, vhCDR3 for the heavy chain and vlCDRl, vlCDR2 and vlCDR3 for the light.
- the CDRs are present in the variable heavy and variable light domains, respectively, and together form an Fv region.
- the six CDRs of the antigen binding domain are contributed by a variable heavy and variable light chain.
- the set of 6 CDRs are contributed by two different polypeptide sequences, the variable heavy domain (vh or VH; containing the vhCDRl, vhCDR2 and vhCDR3) and the variable light domain (vl or VL; containing the vlCDRl, vlCDR2 and vlCDR3), with the C-terminus of the vh domain being attached to the N- terminus of the CHI domain of the heavy chain and the C-terminus of the vl domain being attached to the N-terminus of the constant light domain (and thus forming the light chain).
- the vh and vl domains are covalently attached, generally through the use of a linker as outlined herein, into a single polypeptide sequence, which can be either (starting from the N-terminus) vh-linker-vl or vl-linker-vh, with the former being generally preferred (including optional domain linkers on each side, depending on the format used.
- modification herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence or an alteration to a moiety chemically linked to a protein.
- a modification may be an altered carbohydrate or PEG structure attached to a protein.
- amino acid modification herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence.
- the amino acid modification is always to an amino acid coded for by DNA, e.g. the 20 amino acids that have codons in DNA and RNA.
- amino acid substitution or “substitution” herein is meant the replacement of an amino acid at a particular position in a parent polypeptide sequence with a different amino acid.
- the substitution is to an amino acid that is not naturally occurring at the particular position, either not naturally occurring within the organism or in any organism.
- substitution E272Y refers to a variant polypeptide, in this case an Fc variant, in which the glutamic acid at position 272 is replaced with tyrosine.
- a protein which has been engineered to change the nucleic acid coding sequence but not change the starting amino acid is not an ''amino acid substitution"; that is, despite the creation of a new gene encoding the same protein, if the protein has the same amino acid at the particular position that it started with, it is not an amino acid substitution.
- amino acid insertion or "insertion” as used herein is meant the addition of an amino acid sequence at a particular position in a parent polypeptide sequence.
- -233E or 233E designates an insertion of glutamic acid after position 233 and before position 234.
- -233 ADE or A233ADE designates an insertion of AlaAspGlu after position 233 and before position 234.
- amino acid deletion or “deletion” as used herein is meant the removal of an amino acid sequence at a particular position in a parent polypeptide sequence.
- E233- or E233#, E233() or E233del designates a deletion of glutamic acid at position 233.
- EDA233- or EDA233# designates a deletion of the sequence GluAspAla that begins at position 233.
- variant protein or “protein variant”, or “variant” as used herein is meant a protein that differs from that of a parent protein by virtue of at least one amino acid modification.
- Protein variant may refer to the protein itself, a composition comprising the protein, or the amino sequence that encodes it.
- the protein variant has at least one amino acid modification compared to the parent protein, e.g. from about one to about seventy amino acid modifications, and preferably from about one to about five amino acid modifications compared to the parent.
- the parent polypeptide for example an Fc parent polypeptide
- the protein variant sequence herein will preferably possess at least about 80% identity with a parent protein sequence, and most preferably at least about 90% identity, more preferably at least about 95-98-99% identity.
- Variant protein can refer to the variant protein itself, compositions comprising the protein variant, or the DNA sequence that encodes it.
- antibody variant or “variant antibody” as used herein is meant an antibody that differs from a parent antibody by virtue of at least one amino acid modification
- IgG variant or “variant IgG” as used herein is meant an antibody that differs from a parent IgG (again, in many cases, from a human IgG sequence) by virtue of at least one amino acid modification
- immunoglobulin variant or “variant immunoglobulin” as used herein is meant an immunoglobulin sequence that differs from that of a parent immunoglobulin sequence by virtue of at least one amino acid modification.
- Fc variant or “variant Fc” as used herein is meant a protein comprising an amino acid modification in an Fc domain.
- the Fc variants of the present invention are defined according to the amino acid modifications that compose them.
- N434S or 434S is an Fc variant with the substitution serine at position 434 relative to the parent Fc polypeptide, wherein the numbering is according to the EU index.
- M428L/N434S defines an Fc variant with the substitutions M428L and N434S relative to the parent Fc polypeptide.
- the identity of the WT amino acid may be unspecified, in which case the aforementioned variant is referred to as 428L/434S.
- substitutions are provided is arbitrary, that is to say that, for example, 428L/434S is the same Fc variant as M428L/ 434S, and so on.
- amino acid position numbering is according to the EU index.
- the EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, hereby entirely incorporated by reference.)
- the modification can be an addition, deletion, or substitution.
- substitutions can include naturally occurring amino acids and, in some cases, synthetic amino acids. Examples include U.S. Pat. No.
- protein herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides.
- the peptidyl group may comprise naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures, i.e. "analogs", such as peptoids (see Simon et al., PNAS USA 89(20):9367 (1992), entirely incorporated by reference).
- the amino acids may either be naturally occurring or synthetic (e.g. not an amino acid that is coded for by DNA); as will be appreciated by those in the art.
- homo-phenylalanine, dtrulline, ornithine and noreleucine are considered synthetic amino acids for the purposes of the invention, and both D- and L-(R or S) configured amino acids may be utilized.
- the variants of the present invention may comprise modifications that include the use of synthetic amino acids incorporated using, for example, the technologies developed by Schultz and colleagues, including but not limited to methods described by Cropp & Shultz, 2004, Trends Genet.
- polypeptides may include synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, linkers to other molecules, fusion to proteins or protein domains, and addition of peptide tags or labels.
- residue as used herein is meant a position in a protein and its associated amino acid identity.
- Asparagine 297 also referred to as Asn297 or N297
- Asn297 is a residue at position 297 in the human antibody IgGl.
- Fab or "Fab region” as used herein is meant the polypeptide that comprises the VH, CHI, VL, and CL immunoglobulin domains. Fab may refer to this region in isolation, or this region in the context of a full length antibody, antibody fragment or Fab fusion protein.
- Fv or “Fv fragment” or “Fv region” as used herein is meant a polypeptide that comprises the VL and VH domains of a single ABD. As will be appreciated by those in the art, these generally are made up of two chains, or can be combined (generally with a linker as discussed herein) to form an scFv.
- an "extra” vh and vl domain is added that serves as a scFv but where the vh and vl domains are not linked using a scFv linker between them.
- single chain Fv or “scFv” herein is meant a variable heavy domain covalently attached to a variable light domain, generally using a scFv linker as discussed herein, to form a scFv or scFv domain.
- a scFv domain can be in either orientation from N- to C- terminus (vh-linker-vl or vl-linker-vh).
- IgG subclass modification or "isotype modification” as used herein is meant an amino acid modification that converts one amino acid of one IgG isotype to the corresponding amino acid in a different, aligned IgG isotype.
- IgGl comprises a tyrosine and IgG2 a phenylalanine at EU position 296, a F296Y substitution in IgG2 is considered an IgG subclass modification.
- non-naturally occurring modification as used herein is meant an amino acid modification that is not isotypic.
- the substitution 434S in IgGl, IgG2, IgG3, or IgG4 (or hybrids thereof) is considered a non-naturally occurring modification.
- amino acid and “amino acid identity” as used herein is meant one of the amino acids
- effector function as used herein is meant a biochemical event that results from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include but are not limited to ADCC, ADCP, and CDC.
- IgG Fc ligand as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an IgG antibody to form an Fc/Fc ligand complex.
- Fc ligands include but are not limited to FcyRIs, FcyRIIs, FcyRIIIs, FcRn, Clq, C3, mannan binding lectin, mannose receptor, staphylococcal protein A, streptococcal protein G, and viral FcyR.
- Fc ligands also include Fc receptor homologs (FcRH), which are a family of Fc receptors that are homologous to the FcyRs (Davis et al., 2002, Immunological Reviews 190:123-136, entirely incorporated by reference).
- Fc ligands may include undiscovered molecules that bind Fc. Particular IgG Fc ligands are FcRn and Fc gamma receptors.
- Fc ligand as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an antibody to form an Fc/Fc ligand complex.
- Fc gamma receptor any member of the family of proteins that bind the IgG antibody Fc region and is encoded by an FcyR gene.
- this family includes but is not limited to FcyRI (CD64), including isoforms FcyRIa, FcyRIb, and FcyRIc; FcyRII (CD32), including isoforms FcyRIIa (including allotypes H131 and R131), FcyRIIb (including FcyRIIb-l and FcyRIIb-2), and FcyRIIc; and FcyRIII (CD16), including isoforms FcyRIIIa (including allotypes V158 and F158) and FcyRIIIb (including allotypes FcyRIIb-NAl and FcyRIIb-NA2) (Jefferis et al., 2002, Immunol Lett 82:57-65, entirely incorporated by reference), as well as any undiscovered human FcyRs or FcyR isoforms or allotypes.
- An FcyR may be from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys.
- Mouse FcyRs include but are not limited to FcyRI (CD64), FcyRII (CD32), FcyRIII (CD16), and FcyRIII-2 (CD16-2), as well as any undiscovered mouse FcyRs or FcyR isoforms or allotypes.
- FcRn or "neonatal Fc Receptor” as used herein is meant a protein that binds the IgG antibody Fc region and is encoded at least in part by an FcRn gene.
- the FcRn may be from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys.
- the functional FcRn protein comprises two polypeptides, often referred to as the heavy chain and light chain.
- the light chain is beta-2-microglobulin and the heavy chain is encoded by the FcRn gene.
- FcRn or an FcRn protein refers to the complex of FcRn heavy chain with beta-2-microglobulin.
- a variety of FcRn variants used to increase binding to the FcRn receptor, and in some cases, to increase serum half-life, are shown in the Figure Legend of Figure 83.
- parent polypeptide as used herein is meant a starting polypeptide that is subsequently modified to generate a variant.
- the parent polypeptide may be a naturally occurring polypeptide, or a variant or engineered version of a naturally occurring polypeptide.
- Parent polypeptide may refer to the polypeptide itself, compositions that comprise the parent polypeptide, or the amino acid sequence that encodes it.
- parent immunoglobulin'' as used herein is meant an unmodified immunoglobulin polypeptide that is modified to generate a variant
- parent antibody as used herein is meant an unmodified antibody that is modified to generate a variant antibody. It should be noted that "parent antibody” includes known commercial, recombinantly produced antibodies as outlined below.
- Fc or “Fc region” or “Fc domain” as used herein is meant the polypeptide comprising the constant region of an antibody excluding the first constant region immunoglobulin domain and in some cases, part of the hinge.
- Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains.
- Fc may include the J chain.
- the Fc domain comprises immunoglobulin domains Cy2 and Cy3 (Cy2 and Cy3) and the lower hinge region between Cyl (Cyl) and Cy2 (Cy2).
- the human IgG heavy chain Fc region is usually defined to include residues C226 or P230 to its carboxyl-terminus, wherein the numbering is according to the EU index as in Kabat.
- amino acid modifications are made to the Fc region, for example to alter binding to one or more FcyR receptors or to the FcRn receptor.
- Fc fusion protein or “immunoadhesin” herein is meant a protein comprising an Fc region, generally linked (optionally through a linker moiety, as described herein) to a different protein, such as a binding moiety to a target protein, as described herein.
- one monomer of the heterodimeric antibody comprises an antibody heavy chain (either including an scFv or further including a light chain) and the other monomer is a Fc fusion, comprising a variant Fc domain and a ligand.
- these "half antibody-half fusion proteins” are referred to as "Fusionbodies”.
- position as used herein is meant a location in the sequence of a protein.
- Positions may be numbered sequentially, or according to an established format, for example the EU index for antibody numbering.
- target antigen as used herein is meant the molecule that is bound specifically by the variable region of a given antibody.
- a target antigen may be a protein, carbohydrate, lipid, or other chemical compound. Suitable target antigens are described below.
- strandedness in the context of the monomers of the heterodimeric antibodies of the invention herein is meant that, similar to the two strands of DNA that "match”, heterodimerization variants are incorporated into each monomer so as to preserve the ability to "match” to form heterodimers.
- some pi variants are engineered into monomer A (e.g. making the pi higher) then steric variants that are "charge pairs” that can be utilized as well do not interfere with the pi variants, e.g. the charge variants that make a pi higher are put on the same "strand" or "monomer” to preserve both
- target cell as used herein is meant a cell that expresses a target antigen.
- variable region as used herein is meant the region of an immunoglobulin that comprises one or more Ig domains substantially encoded by any of the V.kappa., V.lamda., and/or VH genes that make up the kappa, lambda, and heavy chain
- wild type or WT herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations.
- a WT protein has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
- the antibodies of the present invention are generally isolated or recombinant.
- isolated when used to describe the various polypeptides disclosed herein, means a polypeptide that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Ordinarily, an isolated polypeptide will be prepared by at least one purification step.
- Recombinant means the antibodies are generated using recombinant nucleic acid techniques in exogeneous host cells.
- Percent (%) amino acid sequence identity with respect to a protein sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific (parental) sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. One particular program is the ALIGN-2 program outlined at paragraphs [0279] to [0280] of US Pub. No. 20160244525, hereby incorporated by reference.
- invention sequence The degree of identity between an amino acid sequence of the present invention
- parental amino acid sequence is calculated as the number of exact matches in an alignment of the two sequences, divided by the length of the "invention sequence,” or the length of the parental sequence, whichever is the shortest. The result is expressed in percent identity.
- two or more amino acid sequences are at least 50%
- two or more amino acid sequences are at least 95%, 97%, 98%, 99%, or even 100% identical.
- Specific binding or “specifically binds to” or is “specific for” a particular antigen or an epitope means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.
- Specific binding for a particular antigen or an epitope can be exhibited, for example, by an antibody having a KD for an antigen or epitope of at least about 10 4 M, at least about 10 5 M, at least about 10 6 M, at least about 10 7 M, at least about 10 8 M, at least about 10- 9 M, alternatively at least about 10 10 M, at least about 10 11 M, at least about 10 12 M, or greater, where KD refers to a dissociation rate of a particular antibody-antigen interaction.
- an antibody that specifically binds an antigen will have a KD that is 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for a control molecule relative to the antigen or epitope.
- binding for a particular antigen or an epitope can be exhibited, for example, by an antibody having a KA or Ka for an antigen or epitope of at least 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for the epitope relative to a control, where KA or Ka refers to an association rate of a particular antibody-antigen interaction. Binding affinity is generally measured using a Biacore assay.
- the present invention relates to the generation of bispecific
- immunomodulatory antibodies that bind two different immunomodulatory antigens as discussed herein.
- antibody is used generally.
- Antibodies that find use in the present invention can take on a number of formats as described herein.
- Traditional antibody structural units typically comprise a tetramer. Each tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one "light” (typically having a molecular weight of about 25 kDa) and one "heavy” chain (typically having a molecular weight of about 50-70 kDa). Human light chains are classified as kappa and lambda light chains.
- the present invention is directed to bispecific antibodies that generally are based on the IgG class, which has several subclasses, including, but not limited to IgGl, IgG2, IgG3, and IgG4. In general, IgGl, IgG2 and IgG4 are used more frequently than IgG3. It should be noted that IgGl has different allotypes with
- the sequences depicted herein use the 356D/358M allotype, however the other allotype is included herein. That is, any sequence inclusive of an IgGl Fc domain included herein can have 356E/358L replacing the
- cysteines at position 220 have at least one of the cysteines at position 220 replaced by a serine; generally, this is the on the "scFv monomer” side for most of the sequences depicted herein, although it can also be on the "Fab monomer” side, or both, to reduce disulfide formation.
- cysteines replaced (C220S).
- therapeutic antibodies defined by the chemical and antigenic characteristics of their constant regions. It should be understood that therapeutic antibodies can also comprise hybrids of isotypes and/or subclasses. For example, as shown in US Publication 2009/0163699, incorporated by reference, the present invention covers pi engineering of IgGl/G2 hybrids.
- ammo-terminal portion of each chain includes a variable region of about
- variable domain 100 to 110 or more amino acids primarily responsible for antigen recognition, generally referred to in the art and herein as the "Fv domain” or “Fv region".
- Fv domain 100 to 110 or more amino acids primarily responsible for antigen recognition
- CDR complementarity- determining region
- Variable refers to the fact that certain segments of the variable region differ extensively in sequence among antibodies. Variability within the variable region is not evenly distributed. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called “hypervariable regions” that are each 9-15 amino acids long or longer.
- Each VH and VL is composed of three hypervariable regions
- CDRs complementary determining regions
- the hypervariable region generally encompasses amino acid residues from about amino acid residues 24-34 (LCDRl; “L” denotes light chain), 50-56 (LCDR2) and 89-97 (LCDR3) in the light chain variable region and around about 31-35B (HCDRl; “H” denotes heavy chain), 50-65 (HCDR2), and 95-102 (HCDR3) in the heavy chain variable region; Kabat et al SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) and/or those residues forming a hypervariable loop (e.g.
- variable heavy and/or variable light sequence includes the disclosure of the associated (inherent) CDRs. Accordingly, the disclosure of each variable heavy region is a disclosure of the vhCDRs (e.g. vhCDRl, vhCDR2 and vhCDR3) and the disclosure of each variable light region is a disclosure of the vlCDRs (e.g. vlCDRl, vlCDR2 and vlCDR3).
- the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately, residues 1-107 of the light chain variable region and residues 1-113 of the heavy chain variable region) and the EU numbering system for Fc regions (e.g, Kabat et al., supra (1991)).
- a "full CDR set” comprises the three variable light and three variable heavy CDRs, e.g. a vlCDRl, vlCDR2, vlCDR3, vhCDRl, vhCDR2 and vhCDR3. These can be part of a larger variable light or variable heavy domain, respectfully.
- the variable heavy and variable light domains can be on separate polypeptide chains, when a heavy and light chain is used (for example when Fabs are used), or on a single polypeptide chain in the case of scFv sequences.
- the CDRs contribute to the formation of the antigen-binding, or more specifically, epitope binding site of antibodies.
- Epitope refers to a determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. Epitopes are groupings of molecules such as amino acids or sugar side chains and usually have specific structural characteristics, as well as specific charge characteristics. A single antigen may have more than one epitope.
- the epitope may comprise amino acid residues directly involved in the binding (also called immunodominant component of the epitope) and other amino acid residues, which are not directly involved in the binding, such as amino acid residues which are effectively blocked by the specifically antigen binding peptide; in other words, the amino acid residue is within the footprint of the specifically antigen binding peptide.
- Epitopes may be either conformational or linear.
- a conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain.
- a linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. Conformational and nonconf ormational epitopes may be distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
- An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.
- Antibodies that recognize the same epitope can be verified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen, for example "binning.”
- the invention not only includes the enumerated antigen binding domains and antibodies herein, but those that compete for binding with the epitopes bound by the enumerated antigen binding domains.
- each chain defines a constant region primarily responsible for effector function.
- Kabat et al. collected numerous primary sequences of the variable regions of heavy chains and light chains. Based on the degree of conservation of the sequences, they classified individual primary sequences into the CDR and the framework and made a list thereof (see SEQUENCES OF IMMUNOLOGICAL INTEREST, 5th edition, NIH publication, No. 91-3242, E.A. Kabat et al., entirely incorporated by reference).
- immunoglobulin domains in the heavy chain.
- immunoglobulin (Ig) domain herein is meant a region of an immunoglobulin having a distinct tertiary structure.
- the heavy chain domains including, the constant heavy (CH) domains and the hinge domains.
- the IgG isotypes each have three CH regions. Accordingly, "CH” domains in the context of IgG are as follows: “CHI” refers to positions 118-220 according to the EU index as in Kabat.
- CH2 refers to positions 237-340 according to the EU index as in Kabat
- CH3 refers to positions 341-447 according to the EU index as in Kabat.
- the pi variants can be in one or more of the CH regions, as well as the hinge region, discussed below.
- Ig domain of the heavy chain is the hinge region.
- hinge region or “hinge region” or “antibody hinge region” or “immunoglobulin hinge region” herein is meant the flexible polypeptide comprising the amino acids between the first and second constant domains of an antibody.
- the IgG CHI domain ends at EU position 220, and the IgG CH2 domain begins at residue EU position 237.
- the antibody hinge is herein defined to include positions 221 (D221 in IgGl) to 236 (G236 in IgGl), wherein the numbering is according to the EU index as in Kabat.
- the lower hinge is included, with the “lower hinge” generally referring to positions 226 or 230.
- pi variants can be made in the hinge region as well.
- the light chain generally comprises two domains, the variable light domain
- the present invention provides different antibody domains.
- the heterodimeric antibodies of the invention comprise different domains within the heavy and light chains, which can be overlapping as well. These domains include, but are not limited to, the Fc domain, the CHI domain, the CH2 domain, the CH3 domain, the hinge domain, the heavy constant domain (CHl-hinge- Fc domain or CHl-hinge-CH2-CH3), the variable heavy domain, the variable light domain, the light constant domain, Fab domains and scFv domains.
- the "Fc domain” includes the -CH2-CH3 domain, and optionally a hinge domain.
- a scFv when a scFv is attached to an Fc domain, it is the C-terminus of the scFv construct that is attached to all or part of the hinge of the Fc domain; for example, it is generally attached to the sequence EPKS which is the beginning of the hinge.
- the heavy chain comprises a variable heavy domain and a constant domain, which includes a CHI-optional hinge-Fc domain comprising a CH2-CH3.
- the light chain comprises a variable light chain and the light constant domain.
- a scFv comprises a variable heavy chain, an scFv linker, and a variable light domain.
- C-terminus of the variable light chain is attached to the N- terminus of the scFv linker, the C-terminus of which is attached to the N-terminus of a variable heavy chain (N-vh-linker-vl-C) although that can be switched (N-vl-linker-vh-C).
- Some embodiments of the invention comprise at least one scFv domain, which, while not naturally occurring, generally includes a variable heavy domain and a variable light domain, linked together by a scFv linker.
- the scFv domain is generally from N- to C-terminus oriented as vh-scFv linker-vl, this can be reversed for any of the scFv domains (or those constructed using vh and vl sequences from Fabs), to vl-scFv linker-vh, with optional linkers at one or both ends depending on the format (see generally Figure 2).
- linker peptide may predominantly include the following amino acid residues: Gly, Ser, Ala, or Thr.
- the linker peptide should have a length that is adequate to link two molecules in such a way that they assume the correct conformation relative to one another so that they retain the desired activity.
- the linker is from about 1 to 50 amino acids in length, preferably about 1 to 30 amino acids in length.
- linkers of 1 to 20 amino acids in length may be used, with from about 5 to about 10 amino acids finding use in some embodiments.
- Useful linkers include glycine-serine polymers, including for example (GS)n, (GSGGS)n, (GGGGS)n, and (GGGS)n, where n is an integer of at least one (and generally from 3 to 4), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers.
- glycine-serine polymers including for example (GS)n, (GSGGS)n, (GGGGS)n, and (GGGS)n, where n is an integer of at least one (and generally from 3 to 4), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers.
- nonproteinaceous polymers including but not limited to polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol, may find use as linkers, that is may find use as linkers.
- linker sequences may include any sequence of any length of CL/CH1 domain but not all residues of CL/CH1 domain; for example the first 5-12 amino acid residues of the CL/CH1 domains.
- Linkers can be derived from immunoglobulin light chain, for example CK or CX.
- Linkers can be derived from immunoglobulin heavy chains of any isotype, including for example Cyl, Cy2, Cy3, Cy4, Cocl, Coc2, C8, Cs, and C ⁇ .
- Linker sequences may also be derived from other proteins such as Ig-like proteins (e.g. TCR, FcR, KIR), hinge region-derived sequences, and other natural sequences from other proteins.
- the linker is a "domain linker", used to link any two domains as outlined herein together. While any suitable linker can be used, many embodiments utilize a glycine-serine polymer, including for example (GS)n, (GSGGS)n, (GGGGS)n, and (GGGS)n, where n is an integer of at least one (and generally from 3 to 4 to 5) as well as any peptide sequence that allows for recombinant attachment of the two domains with sufficient length and flexibility to allow each domain to retain its biological function. . In some cases, and with attention being paid to "strandedness", as outlined below, charged domain linkers, as used in some embodiments of scFv linkers can be used.
- the scFv linker is a charged scFv linker, a number of which are shown in Figure 8. Accordingly, the present invention further provides charged scFv linkers, to facilitate the separation in pi between a first and a second monomer. That is, by incorporating a charged scFv linker, either positive or negative (or both, in the case of scaffolds that use scFvs on different monomers), this allows the monomer comprising the charged linker to alter the pi without making further changes in the Fc domains. These charged linkers can be substituted into any scFv containing standard linkers.
- charged scFv linkers are used on the correct "strand" or monomer, according to the desired changes in pi.
- the original pi of the Fv region for each of the desired antigen binding domains are calculated, and one is chosen to make an scFv, and depending on the pi, either positive or negative linkers are chosen.
- Charged domain linkers can also be used to increase the pi separation of the monomers of the invention as well, and thus those included in Figure 8 can be used in any embodiment herein where a linker is utilized.
- the antibody is an antibody fragment, as long as it contains at least one constant domain which can be engineered to produce heterodimers, such as pi engineering.
- Other antibody fragments that can be used include fragments that contain one or more of the CHI, CH2, CH3, hinge and CL domains of the invention that have been pi engineered.
- the formats depicted in Figure 1 are antibodies, usually referred to as "heterodimeric antibodies", meaning that the protein has at least two associated Fc sequences self-assembled into a heterodimeric Fc domain and at least two Fv regions, whether as Fabs or as scFvs.
- the antibodies herein can be derived from a mixture from different species, e.g. a chimeric antibody and/or a humanized antibody.
- both ''chimeric antibodies” and “humanized antibodies” refer to antibodies that combine regions from more than one species.
- ''chimeric antibodies traditionally comprise variable region(s) from a mouse (or rat, in some cases) and the constant region(s) from a human.
- Humanized antibodies generally refer to non-human antibodies that have had the variable-domain framework regions swapped for sequences found in human antibodies.
- a humanized antibody the entire antibody, except the CDRs, is encoded by a polynucleotide of human origin or is identical to such an antibody except within its CDRs.
- the CDRs some or all of which are encoded by nucleic acids originating in a non-human organism, are grafted into the beta-sheet framework of a human antibody variable region to create an antibody, the specificity of which is determined by the engrafted CDRs.
- the creation of such antibodies is described in, e.g., WO 92/11018, Jones, 1986, Nature 321:522-525, Verhoeyen et al., 1988, Science 239:1534-1536, all entirely incorporated by reference.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region, typically that of a human immunoglobulin, and thus will typically comprise a human Fc region.
- Humanized antibodies can also be generated using mice with a genetically engineered immune system. Roque et al., 2004, Biotechnol. Prog. 20:639-654, entirely incorporated by reference.
- Humanization methods include but are not limited to methods described in Jones et al., 1986, Nature 321:522-525; Riechmann et al.,1988; Nature 332:323-329; Verhoeyen et al., 1988, Science, 239:1534-1536; Queen et al., 1989, Proc Natl Acad Sci, USA 86:10029-33; He et al., 1998, J. Immunol. 160: 1029-1035; Carter et al., 1992, Proc Natl Acad Sci USA 89:4285-9, Presta et al., 1997, Cancer Res. 57(20) :4593-9; Gorman et al., 1991, Proc. Natl.
- Humanization or other methods of reducing the immunogenicity of nonhuman antibody variable regions may include resurfacing methods, as described for example in Roguska et al., 1994, Proc. Natl. Acad. Sci. USA 91:969-973, entirely incorporated by reference.
- the antibodies of the invention comprise a heavy chain variable region from a particular germline heavy chain immunoglobulin gene and/or a light chain variable region from a particular germline light chain immunoglobulin gene.
- such antibodies may comprise or consist of a human antibody comprising heavy or light chain variable regions that are "the product of” or "derived from” a particular germline sequence.
- a human antibody that is "the product of” or “derived from” a human germline immunoglobulin sequence can be identified as such by comparing the amino acid sequence of the human antibody to the amino acid sequences of human germline immunoglobulins and selecting the human germline immunoglobulin sequence that is closest in sequence (i.e., greatest % identity) to the sequence of the human antibody.
- a human antibody that is "the product of” or “derived from” a particular human germline immunoglobulin sequence may contain amino acid differences as compared to the germline sequence, due to, for example, naturally-occurring somatic mutations or intentional introduction of site-directed mutation.
- a humanized antibody typically is at least 90% identical in amino acids sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and contains amino acid residues that identify the antibody as being derived from human sequences when compared to the germline immunoglobulin amino acid sequences of other species (e.g., murine germline sequences).
- a humanized antibody may be at least 95, 96, 97, 98 or 99%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene.
- a humanized antibody derived from a particular human germline sequence will display no more than 10-20 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene (prior to the introduction of any skew, pi and ablation variants herein; that is, the number of variants is generally low, prior to the introduction of the variants of the invention).
- the humanized antibody may display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene (again, prior to the introduction of any skew, pi and ablation variants herein; that is, the number of variants is generally low, prior to the introduction of the variants of the invention).
- the parent antibody has been affinity matured, as is known in the art.
- Structure-based methods may be employed for humanization and affinity maturation, for example as described in USSN 11/004,590.
- Selection based methods may be employed to humanize and/or affinity mature antibody variable regions, including but not limited to methods described in Wu et al., 1999, J. Mol. Biol. 294:151-162; Baca et al., 1997, J. Biol. Chem. 272(16):10678-10684; Rosok et al., 1996, J. Biol. Chem. 271(37): 22611-22618; Rader et al., 1998, Proc. Natl. Acad. Sci.
- the present invention provides heterodimeric immunomodulatory antibodies that rely on the use of two different heavy chain variant Fc sequences, that will self-assemble to form heterodimeric Fc domains and heterodimeric antibodies.
- the present invention is directed to novel constructs to provide heterodimeric antibodies that allow binding to more than one immunomodulatory antigen or ligand, e.g. to allow for bispecific binding.
- the heterodimeric antibody constructs are based on the self- assembling nature of the two Fc domains of the heavy chains of antibodies, e.g. two
- heterodimeric antibodies are made by altering the amino acid sequence of each monomer as more fully discussed below.
- the present invention is generally directed to the creation of heterodimeric immunomodulatory antibodies which can co-engage antigens in several ways, relying on amino acid variants in the constant regions that are different on each chain to promote heterodimeric formation and/or allow for ease of purification of heterodimers over the homodimers.
- the present invention provides bispecific antibodies.
- An ongoing problem in antibody technologies is the desire for "bispecific" antibodies that bind to two different antigens simultaneously, in general thus allowing the different antigens to be brought into proximity and resulting in new functionalities and new therapies.
- these antibodies are made by including genes for each heavy and light chain into the host cells. This generally results in the formation of the desired heterodimer (A-B), as well as the two homodimers (A-A and B-B (not including the light chain heterodimeric issues)).
- bispecific antibodies a major obstacle in the formation of bispecific antibodies is the difficulty in purifying the heterodimeric antibodies away from the homodimeric antibodies and/or biasing the formation of the heterodimer over the formation of the homodimers.
- heterodimerization variants amino acid variants that lead to the production of heterodimers are referred to as “heterodimerization variants”.
- heterodimerization variants can include steric variants (e.g. the "knobs and holes” or “skew” variants described below and the “charge pairs” variants described below) as well as “pi variants", which allows purification of homodimers away from heterodimers.
- heterodimerization variants useful mechanisms for heterodimerization include “knobs and holes” ("KIH”; sometimes herein as “skew” variants (see discussion in WO2014/145806), “electrostatic steering” or “charge pairs” as described in WO2014/145806, pi variants as described in WO2014/145806, and general additional Fc variants as outlined in WO2014/145806 and below.
- KH knock-hole
- skew electrostatic steering
- charge pairs as described in WO2014/145806
- pi variants as described in WO2014/145806
- general additional Fc variants as outlined in WO2014/145806 and below.
- embodiments of particular use in the present invention rely on sets of variants that include skew variants, that encourage heterodimerization formation over homodimerization formation, coupled with pi variants, which increase the pi difference between the two monomers.
- pi variants can be either contained within the constant and/or Fc domains of a monomer, or charged linkers, either domain linkers or scFv linkers, can be used. That is, scaffolds that utilize scFv(s) such as the Triple F format can include charged scFv linkers (either positive or negative), that give a further pi boost for purification purposes. As will be appreciated by those in the art, some Triple F formats are useful with just charged scFv linkers and no additional pi adjustments, although the invention does provide pi variants that are on one or both of the monomers, and/or charged domain linkers as well. In addition, additional amino acid engineering for alternative functionalities may also confer pi changes, such as Fc, FcRn and KO variants.
- amino acid variants can be introduced into one or both of the monomer polypeptides; that is, the pi of one of the monomers (referred to herein for simplicity as "monomer A”) can be engineered away from monomer B, or both monomer A and B change be changed, with the pi of monomer A increasing and the pi of monomer B decreasing.
- the pi changes of either or both monomers can be done by removing or adding a charged residue (e.g. a neutral amino acid is replaced by a positively or negatively charged amino acid residue, e.g.
- this embodiment of the present invention provides for creating a sufficient change in pi in at least one of the monomers such that heterodimers can be separated from homodimers.
- this can be done by using a "wild type" heavy chain constant region and a variant region that has been engineered to either increase or decrease its pi (wt A-+B or wt A - -B), or by increasing one region and decreasing the other region (A+ -B- or A- B+).
- a component of some embodiments of the present invention are amino acid variants in the constant regions of antibodies that are directed to altering the isoelectric point (pi) of at least one, if not both, of the monomers of a dimeric protein to form "pi antibodies” by incorporating amino acid substitutions ("pi variants" or "pi
- the separation of the heterodimers from the two homodimers can be accomplished if the pis of the two monomers differ by as little as 0.1 pH unit, with 0.2, 0.3, 0.4 and 0.5 or greater all finding use in the present invention.
- the number of pi variants to be included on each or both monomer(s) to get good separation will depend in part on the starting pi of the components, for example in the triple F format, the starting pi of the scFv and Fab of interest. That is, to determine which monomer to engineer or in which "direction" (e.g. more positive or more negative), the Fv sequences of the two target antigens are calculated and a decision is made from there. As is known in the art, different Fvs will have different starting pis which are exploited in the present invention.
- the pis are engineered to result in a total pi difference of each monomer of at least about 0.1 logs, with 0.2 to 0.5 being preferred as outlined herein.
- heterodimers can be separated from homodimers on the basis of size. As shown in Figure 2, for example, several of the formats allow separation of heterodimers and homodimers on the basis of size.
- the present invention provides heterodimeric proteins, including
- heterodimeric antibodies in a variety of formats, which utilize heterodimeric variants to allow for heterodimeric formation and/or purification away from homodimers.
- a number of heterodimerization variants are shown in Figure 4.
- these sets do not necessarily behave as "knobs in holes" variants, with a one-to-one correspondence between a residue on one monomer and a residue on the other; that is, these pairs of sets form an interface between the two monomers that encourages heterodimer formation and discourages homodimer formation, allowing the percentage of heterodimers that spontaneously form under biological conditions to be over 90%, rather than the expected 50% (25 % homodimer A/A:50% heterodimer A B:25% homodimer B B).
- the formation of heterodimers can be facilitated by the addition of steric variants. That is, by changing amino acids in each heavy chain, different heavy chains are more likely to associate to form the heterodimeric structure than to form homodimers with the same Fc amino acid sequences. Suitable steric variants are included in in the Figures.
- knocks and holes referring to amino acid engineering that creates steric influences to favor heterodimeric formation and disfavor homodimeric formation can also optionally be used; this is sometimes referred to as “knobs and holes”, as described in USSN 61/596,846, Ridgway et al., Protein Engineering 9(7):617 (1996); Atwell et al., J. Mol. Biol. 1997 270:26; US Patent No. 8,216,805, all of which are hereby incorporated by reference in their entirety.
- the Figures identify a number of "monomer A - monomer B" pairs that rely on “knobs and holes”.
- these "knobs and hole” mutations can be combined with disulfide bonds to skew formation to
- D221R/P228R/K409R e.g. these are "monomer corresponding sets
- C220E/P228E/368E paired with C220R/E224R/P228R/K409R.
- the steric variants outlined herein can be optionally and independently incorporated with any pi variant (or other variants such as Fc variants, FcRn variants, etc.) into one or both monomers, and can be independently and optionally included or excluded from the proteins of the invention.
- a list of suitable skew variants is found in Figure 4 showing some pairs of particular utility in many embodiments.
- the pairs of sets including, but not limited to, S364K/E357Q : L368D/ 370S; L368D/ 370S : S364K; L368E/ 370S : S364K; T411T/E360E/Q362E : D401K; L368D/ 370S : S364K/E357L, K370S : S364K/E357Q and T366S/L368A/Y407V : T366W (optionally including a bridging disulfide, T366S/L368A/Y407V/Y349C : T366W/S354C).
- the pair "S364K/E357Q: L368D/K370S” means that one of the monomers has the double variant set S364K/E357Q and the other has the double variant set L368D/ 370S; as above, the
- pi variants are two general categories of pi variants: those that increase the pi of the protein (basic changes) and those that decrease the pi of the protein (acidic changes). As described herein, all combinations of these variants can be done: one monomer may be wild type, or a variant that does not display a significantly different pi from wild-type, and the other can be either more basic or more acidic. Alternatively, each monomer is changed, one to more basic and one to more acidic.
- a preferred combination of pi variants has one monomer (the negative Fab side) comprising
- the first monomer includes a CHI domain, including position 208.
- a preferred negative pi variant Fc set includes 295E/384D/418E/421D variants (Q295E/N384D/Q418E/ 421D when relative to human IgGl).
- one monomer has a set of substitutions from Figure 5 and the other monomer has a charged linker (either in the form of a charged scFv linker because that monomer comprises an scFv or a charged domain linker, as the format dictates).
- IgGl is a common isotype for therapeutic antibodies for a variety of reasons, including high effector function.
- the heavy constant region of IgGl has a higher pi than that of IgG2 (8.10 versus 7.31).
- IgG2 residues at particular positions into the IgGl backbone By introducing IgG2 residues at particular positions into the IgGl backbone, the pi of the resulting monomer is lowered (or increased) and additionally exhibits longer serum half-life.
- IgGl has a glycine (pi 5.97) at position 137
- IgG2 has a glutamic acid (pi 3.22); importing the glutamic acid will affect the pi of the resulting protein.
- a number of amino acid substitutions are generally required to significant affect the pi of the variant antibody.
- even changes in IgG2 molecules allow for increased serum half-life.
- non-isotypic amino acid changes are made, either to reduce the overall charge state of the resulting protein (e.g. by changing a higher pi amino acid to a lower pi amino acid), or to allow accommodations in structure for stability, etc. as is more further described below.
- the pi of each monomer can depend on the pi of the variant heavy chain constant domain and the pi of the total monomer, including the variant heavy chain constant domain and the fusion partner.
- the change in pi is calculated on the basis of the variant heavy chain constant domain, using the chart in the Figure 19 of US Pub. 2014/0370013.
- which monomer to engineer is generally decided by the inherent pi of the Fv and scaffold regions.
- the pi of each monomer can be compared.
- variable regions may also have longer serum half-lives (Igawa et al., 2010 PEDS. 23(5): 385-392, entirely incorporated by reference). However, the mechanism of this is still poorly understood. Moreover, variable regions differ from antibody to antibody. Constant region variants with reduced pi and extended half -life would provide a more modular approach to improving the pharmacokinetic properties of antibodies, as described herein.
- Fc amino acid modification In addition to pi amino acid variants, there are a number of useful Fc amino acid modification that can be made for a variety of reasons, including, but not limited to, altering binding to one or more FcyR receptors, altered binding to FcRn receptors, etc.
- proteins of the invention can include amino acid
- heterodimerization variants outlined herein, which includes the pi variants and steric variants.
- Each set of variants can be independently and optionally included or excluded from any particular heterodimeric protein.
- Fc substitutions that can be made to alter binding to one or more of the FcyR receptors.
- Substitutions that result in increased binding as well as decreased binding can be useful.
- ADCC antibody dependent cell-mediated cytotoxicity; the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcyRs recognize bound antibody on a target cell and subsequently cause lysis of the target cell.
- FcyRIIb an inhibitory receptor
- Amino acid substitutions that find use in the present invention include those listed in USSNs 11/124,620 (particularly Figure 41), 11/174,287, 11/396,495, 11/538,406, all of which are expressly incorporated herein by reference in their entirety and specifically for the variants disclosed therein.
- Particular variants that find use include, but are not limited to, 236 A, 239D, 239E, 332E, 332D, 239D/332E, 267D, 267E, 328F, 267E/328F, 236A/332E, 239D/332E/330Y, 239D, 332E/330L, 243 A, 243L, 264A, 264V and 299T.
- Fc substitutions that find use in increased binding to the FcRn receptor and increased serum half life, as specifically disclosed in USSN 12/341,769, hereby incorporated by reference in its entirety, including, but not limited to, 434S, 434A, 428L, 308F, 2591, 428L/434S, 259I/308F, 436I/428L, 4361 or V/434S, 436V/428L and 259I/308F/428L.
- FcyR ablation variants or “Fc knock out (FcKO or KO)” variants.
- FcyR ablation variants or “Fc knock out (FcKO or KO)” variants.
- FcKO or KO Fey receptors
- ablation variants are depicted in Figure 6, and each can be independently and optionally included or excluded, with preferred aspects utilizing ablation variants selected from the group consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V L235A/G236del. It should be noted that the ablation variants referenced herein ablate FcyR binding but generally not FcRn binding.
- heterodimerization variants including skew and/or pi variants
- skew and/or pi variants can be optionally and independently combined in any way, as long as they retain their "strandedness" or "monomer partition”.
- all of these variants can be combined into any of the heterodimerization formats.
- any of the heterodimerization variants, skew and pi are also independently and optionally combined with Fc ablation variants, Fc variants, FcRn variants, as generally outlined herein.
- the bispecific heterodimeric antibodies of the present invention can take on a wide variety of configurations, as are generally depicted in Figure 2. Some figures depict “single ended” configurations, where there is one type of specificity on one "arm” of the molecule and a different specificity on the other "arm”. Other figures depict “dual ended” configurations, where there is at least one type of specificity at the "top” of the molecule and one or more different specificities at the "bottom” of the molecule. Thus, the present invention is directed to novel immunoglobulin compositions that co-engage a different first and a second antigen.
- Figure 2 of the invention can have different valencies as well as be bispecific. That is, antibodies of the invention can be bivalent and bispecific, wherein a checkpoint target is bound by one ABD and the costimulatory target is bound by a second ABD (see for example the bottle opener format which is heterodimeric) or the bispecific mAb which is
- the heterodimeric antibodies can also be trivalent and bispecific, wherein the first antigen is bound by two ABDs and the second antigen by a second ABD (see for example the Central-scFv format and the trident format).
- the heterodimeric antibodies can also be bispecific and tetravalent (such as the Central scFv2 format and the DVD-lg format).
- the antibodies are generally formatted such that the co-stimulatory target is bound monovalently.
- One heterodimeric scaffold that finds particular use in the present invention is the "triple F” or “bottle opener” scaffold format.
- one heavy chain of the antibody contains a single chain Fv ("scFv", as defined below) and the other heavy chain is a "regular” Fab format, comprising a variable heavy chain and a light chain.
- This structure is sometimes referred to herein as “triple F” format (scFv-Fab-Fc) or the "bottle- opener” format, due to a rough visual similarity to a bottle-opener.
- the two chains are brought together by the use of amino acid variants in the constant regions (e.g. the Fc domain, the CHI domain and/or the hinge region) that promote the formation of heterodimeric antibodies as is described more fully below.
- the bottle opener format that comprises a first monomer comprising an scFv, comprising a variable heavy and a variable light domain, covalently attached using an scFv linker (charged, in many but not all instances), where the scFv is covalently attached to the N-terminus of a first Fc domain usually through a domain linker (which, as outlined herein can either be un-charged or charged and can be exogeneous or endogeneous (e.g. all or part of the native hinge domain).
- the second monomer of the bottle opener format is a heavy chain, and the composition further comprises a light chain.
- the Fc domains of the bottle opener format generally comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q :
- the bottle opener format includes skew variants, pi variants, and ablation variants.
- some embodiments include bottle opener formats that comprise: a) a first monomer (the "scFv monomer") that comprises a charged scFv linker (with the +H sequence of Figure 8 being preferred in some embodiments), the skew variants S364K E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and an Fv that binds to one target as outlined herein; b) a second monomer (the "Fab monomer”) that comprises the skew variants L368D/ 370S, the pi variants
- suitable monomer Fv pairs include (Fabs listed first, scFvs second) ICOS X PD- 1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG
- some embodiments include bottle opener formats that comprise: a) a first monomer (the "scFv monomer”) that comprises a charged scFv linker (with the +H sequence of Figure 8 being preferred in some embodiments), the skew variants
- variable heavy domain that, with the variable light domain, makes up an Fv that binds to a second target as outlined herein; and c) a light chain.
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB; and [00274] (9) the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- the bottle opener format includes skew variants, pi variants, ablation variants and FcRn variants. Accordingly, some embodiments include bottle opener formats that comprise: a) a first monomer (the "scFv monomer") that comprises a charged scFv linker (with the +H sequence of Figure 8 being preferred in some embodiments), the skew variants S364K/E357Q, the ablation variants
- E233P/L234V/L235A/G236del/S267K the FcRn variants M428L/N434S and an Fv that binds to a first receptor (either a costimulatory or checkpoint receptor) as outlined herein; b) a second monomer (the "Fab monomer") that comprises the skew variants L368D/ 370S, the pi variants N208D/Q295E/N384D/ Q418E/N421D, the ablation variants
- E233P/L234V/L235A/G236del/S267K the FcRn variants M428L/N434S and a variable heavy domain that, with the variable light domain, makes up an Fv that binds to a second receptor as outlined herein (the other of the costimulatory or checkpoint receptor); and c) a light chain.
- a second receptor as outlined herein (the other of the costimulatory or checkpoint receptor)
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-Ll.
- Figure 9 shows some bottle opener "backbone" sequences that are missing the Fv sequences that can be used in the present invention. That is, Fv sequences for the scFv portion and the Fab portion can be used from any combination of ICOS and PD- 1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-Ll, ICOS and BTLA, ICOS and TIGIT, GITR and TIGIT, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-Ll, GITR and BTLA, OX40 and PD-1, OX40 and TIGIT, OX40 and CTLA-4, IC OX40 OS and LAG-3, OX40 and TIM-3, OX40 and PD-Ll, OX40 and BTLA, 4-1BB and PD-1, 4-1BB and CTLA
- 428L/434S variants specific Fv combinations of use in the present invention include ICOS and PD-1, ICOS and PD-Ll and ICOS and CTLA-4.
- ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193-27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282-26290.
- specific ABDs that bind OX40 include, but are not limited to, Figure 17, Figure 72 and Figure 73 and those listed in SEQ ID NO: 26272-26281.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the mAb-Fv format.
- the format relies on the use of a C-terminal attachment of an "extra" variable heavy domain to one monomer and the C-terminal attachment of an "extra” variable light domain to the other monomer, thus forming a third antigen binding domain (i.e. an "extra” Fv domain), wherein the Fab portions of the two monomers bind one checkpoint target and the "extra" Fv domain binds a costimulatory target.
- the first monomer comprises a first heavy chain, comprising a first variable heavy domain and a first constant heavy domain comprising a first Fc domain, with a first variable light domain covalently attached to the C-terminus of the first Fc domain using a domain linker (vhl-CHl-hinge-CH2-CH3-[optional linker]-vl2).
- the second monomer comprises a second variable heavy domain, a second constant heavy domain comprising a second Fc domain, and a third variable heavy domain covalently attached to the C-terminus of the second Fc domain using a domain linker (vhl-CHl -hinge- CH2-CH3- [optional linker] -vh2.
- This embodiment further utilizes a common light chain comprising a variable light domain and a constant light domain, which associates with the heavy chains to form two identical Fabs that include two identical Fvs.
- the two C- terminally attached variable domains make up the "extra" third Fv.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, "extra" Fv listed second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BTLA, TIGIT X OX40, PD-1 X OX40, PD-Ll X OX40, CTLA-4 X40 X LAG-3
- the Fc domains of the mAb-Fv format comprise skew variants
- T366S L368A/Y407V/Y349C T366W/S354C
- optionally ablation variants including those shown in Figure 6Error! Reference source not found.
- optionally charged scFv linkers including those shown in Figure 8
- the heavy chain comprises pi variants (including those shown in Figure 5Error! Reference source not found.).
- the mAb-Fv format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include mAb-Fv formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P/L234V L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first checkpoint inhibitor, and a second variable heavy domain; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/ 384D/
- the ablation variants E233P L234V/L235A/G236del/S267K and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the first receptor (either a costimulatory receptor or a checkpoint receptor) as outlined herein, and a second variable light chain, that together with the second variable heavy chain forms an Fv (ABD) that binds a second receptor (e.g. the other of the costimulatory or checkpoint receptor; and c) a light chain comprising a first variable light domain and a constant light domain.
- the first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the first receptor (either a costimulatory receptor or a checkpoint receptor) as outlined herein
- a second variable light chain that together with the second variable heavy chain forms an Fv (ABD) that binds a second receptor (e.g. the other of the costimulatory or checkpoint receptor; and
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-lBB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- the mAb-Fv format includes skew variants, pi variants, ablation variants and FcRn variants. Accordingly, some embodiments include mAb-Fv formats that comprise: a) a first monomer that comprises the skew variants S364K E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first checkpoint inhibitor, and a second variable heavy domain; b) a second monomer that comprises the skew variants
- L368D/ 370S the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the first checkpoint inhibitor as outlined herein, and a second variable light chain, that together with the second variable heavy chain forms an Fv (ABD) that binds a second checkpoint inhibitors; and c) a light chain comprising a first variable light domain and a constant light domain.
- specific ABDs that bind human ICOS are [ICOS]_H0L0 and [ICOS]_H0.66_L0, as well as those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- One heterodimeric scaffold that finds particular use in the present invention is the mAb-scFv format.
- the format relies on the use of a C-terminal attachment of an scFv to one of the monomers, thus forming a third antigen binding domain, wherein the Fab portions of the two monomers bind one receptor target and the "extra" scFv domain binds the other receptor target (generally the monovalently bound costimulatory receptor).
- the first monomer comprises a first heavy chain
- scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain in either orientation (vhl -CHI -hinge-CH2-CH3- [optional linker] - vh2-scFv linker-vl2 or vhl-CHl-hinge-CH2-CH3-[optional linker]-vl2-scFv linker-vh2).
- This embodiment further utilizes a common light chain comprising a variable light domain and a constant light domain, which associates with the heavy chains to form two identical Fabs that bind one of the target receptors.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BTLA, TIGIT X OX40, PD-1 X OX40, PD-Ll X OX TIM-3, OX40 X BTLA,
- the Fc domains of the mAb-scFv format generally comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/K370S; L368D/ 370S : S364K; L368E/ 370S : S364K; T411T/E360E/Q362E : D401K; L368D/K370S : S364K E357L, K370S : S364K/E357Q, T366S/L368A/Y407V : T366W and
- skew variants e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/K370S; L368D/ 370S : S36
- T366S L368A/Y407V/Y349C T366W/S354C
- optionally ablation variants including those shown in Figure 6
- optionally charged scFv linkers including those shown in Figure 8
- the heavy chain comprises pi variants (including those shown in Figure 5Error! Reference source not found.).
- the mAb-scFv format includes skew variants, pi variants, and ablation variants.
- some embodiments include bottle opener formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor, and a scFv that binds to the second receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1; [00321] (3) the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- the mAb-scFv format includes skew variants, pi variants, ablation variants and FcRn variants. Accordingly, some embodiments include mAb-scFv formats that comprise: a) a first monomer that comprises the skew variants S364K E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor, and a scFv that binds to the second receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants
- E233P/L234V/L235A/G236del/S267K the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the first checkpoint inhibitor as outlined herein, and c) a light chain comprising a first variable light domain and a constant light domain.
- mAb-scFv backbone 1 (optionally including M428L/N434S) from Figure 75, specific ABDs that bind human ICOS are shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193-27335, 28549-28556 and 28557-28665.
- mAb-scFv backbone 1 (optionally including M428L/N434S) from Figure 75, specific ABDs that bind human GITR are those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282-26290.
- mAb-scFv backbone 1 (optionally including M428L/N434S) from Figure 75, specific ABDs that bind human 4-1BB include those in Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- mAb-scFv backbone 1 (optionally including M428L/N434S) from Figure 75, specific ABDs that bind human PD-L1 include Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the Central-scFv format.
- the format relies on the use of an inserted scFv domain thus forming a third antigen binding domain, wherein the Fab portions of the two monomers bind one receptor target and the "extra" scFv domain binds another (again, generally the costimulatory receptor is bound monovalently).
- the scFv domain is inserted between the Fc domain and the CHl-Fv region of one of the monomers, thus providing a third antigen binding domain.
- one monomer comprises a first heavy chain comprising a first variable heavy domain, a CHI domain (and optional hinge) and Fc domain, with a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain.
- the scFv is covalently attached between the C-terminus of the CHI domain of the heavy constant domain and the N-terminus of the first Fc domain using optional domain linkers (vhl-CHl-[optional linker] -vh2-scFv linker- vl2- [optional linker including the hinge]-CH2- CH3, or the opposite orientation for the scFv, vhl -CHI- [optional linker] -vl2-scFv linker- vh2- [optional linker induding the hinge] -CH2-CH3).
- the optional linker is a hinge or fragment thereof.
- the other monomer is a standard Fab side (e.g.
- This embodiment further utilizes a common light chain comprising a variable light domain and a constant light domain, which associates with the heavy chains to form two identical Fabs that bind a checkpoint inhibitor.
- a common light chain comprising a variable light domain and a constant light domain, which associates with the heavy chains to form two identical Fabs that bind a checkpoint inhibitor.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BT
- the Fc domains of the central scFv format generally comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q :
- the central scFv format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include central scFv formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/ Q418E/N421D, the ablation variants
- E233P/L234V/L235A/G236del/S267K and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the second receptor as outlined herein; and c) a light chain comprising a first variable light domain and a constant light domain.
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- the central scFv format includes skew variants, pi variants, ablation variants and FcRn variants. Accordingly, some embodiments include central-scFv formats that comprise: a) a first monomer that comprises the skew variants S364K E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor and an scFv domain that binds to a second receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, PD-1 X ICOS, ICOS X PD-Ll, PD-Ll X ICOS, ICOS X CTLA-4 and CTLA-4 X ICOS.
- suitable Fvs that bind ICOS include, but are not limited to, shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- suitable Fvs that bind PD-Ll include, but are not limited to, those shown in Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- suitable Fvs that bind GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282-26290.
- suitable Fvs that bind OX40 include, but are not limited to, Figure 17, Figure 72 and Figure 73 and those listed in SEQ ID NO: 26272-26281.
- suitable Fvs that bind 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- One heterodimeric scaffold that finds particular use in the present invention is the Central-scFv2 format, which is bispecific and tetravalent.
- the format relies on the use of two inserted scFv domains thus forming third and fourth antigen binding domains, wherein the Fab portions of the two monomers bind one receptor target and the "extra" scFv domains bind another.
- the scFv domain is inserted between the Fc domain and the CHl-Fv region of the monomers.
- both monomers comprise a first heavy chain comprising a first variable heavy domain, a CHI domain (and optional hinge) and Fc domain, with a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain.
- the scFv is covalently attached between the C-terminus of the CHI domain of the heavy constant domain and the N-terminus of the first Fc domain using optional domain linkers (vhl-CHl- [optional linker] -vh2-scFv linker- vl2- [optional linker including the hinge]- CH2-CH3, or the opposite orientation for the scFv, vhl-CHl- [optional linker] -vl2-scFv linker-vh2- [optional linker including the hinge] -CH2-CH3).
- the optional linker is a hinge or fragment thereof.
- This embodiment further utilizes a common light chain comprising a variable light domain and a constant light domain, which associates with the heavy chains to form two identical Fabs that bind a receptor.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BTLA, TIGIT X OX40, PD-1 X OX40, PD-Ll X OX TIM-3, OX40 X BTLA,
- the Fc domains of the central scFv2 format generally comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q :
- the central scFv2 format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include central scFv formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/ Q418E/N421D, the ablation variants
- E233P/L234V/L235A/G236del/S267K and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the second receptor as outlined herein; and c) a light chain comprising a first variable light domain and a constant light domain.
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1; [00361] (3) the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- the central scFv2 format includes skew variants, pi variants, ablation variants and FcRn variants. Accordingly, some embodiments include central-scFv formats that comprise: a) a first monomer that comprises the skew variants S364K E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor and an scFv domain that binds to a second receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, PD-1 X ICOS, ICOS X PD-L1, PD-L1 X ICOS, ICOS X CTLA-4 and CTLA-4 X ICOS.
- Fabs listed first, scFvs second ICOS X PD-1, PD-1 X ICOS, ICOS X PD-L1, PD-L1 X ICOS, ICOS X CTLA-4 and CTLA-4 X ICOS.
- suitable Fvs that bind ICOS include, but are not limited to, shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- suitable Fvs that bind PD-L1 include, but are not limited to, those shown in Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- suitable Fvs that bind GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282-26290.
- suitable Fvs that bind OX40 include, but are not limited to, Figure 17, Figure 72 and Figure 73 and those listed in SEQ ID NO: 26272-26281.
- suitable Fvs that bind 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- monovalent costimulatory antibodies comprising a single ABD to the target show efficacy in activating T cells.
- the invention provides monovalent, monospecific antibodies as shown in Figure Figure 2N that comprise a heterodimeric Fc domain (for stability).
- one monomer comprises just an Fc domain, while the other monomer is a HC (VHl-CHl-hinge-CH2-CH3).
- This embodiment further utilizes a light chain comprising a variable light domain and a constant light domain, that associates with the heavy chain to form a Fab.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable ABDs bind a costimulatory receptor such as ICOS, GITR, OX40 or 4-1BB.
- ICOS costimulatory receptor
- GITR GITR
- OX40 4-1BB.
- the Fc domains of the comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/ 370S; L368D/K370S : S364K;
- skew variants e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/ 370S; L368D/K370S : S364K;
- L368E/ 370S S364K; T411T E360E/Q362E : D401K; L368D/K370S : S364K E357L, K370S : S364K E357Q, T366S/L368A/Y407V : T366W and T366S/L368A Y407V Y349C :
- T366W/S354C optionally ablation variants (including those shown in Figure 6), and the heavy chain comprises pi variants (including those shown in Figure 5).
- the one armed scFv-mAb format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include formats that comprise: a) a first (Fc) monomer that comprises the skew variants
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-Ll include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the bispecific mAb format, which is bispecific and tetravalent.
- the format relies on the generation of separate homodimeric antibodies which are then recombined.
- this format there is one HC-LC pair (VHl-CHl-hinge-CH2-CH3 and VL1- LC) and a second Hc-LC pair (VH2-CHl-hinge-CH2-CH3 and VL2-LC), e.g. two different heavy chains and two different light chains.
- suitable pairs include ICOS and PD-1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-Ll, ICOS and BTLA, ICOS and TIGIT, GITR and TIGIT, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-Ll, GITR and BTLA, OX40 and PD-1, OX40 and TIGIT, OX40 and CTLA-4, IC OX40 OS and LAG-3, OX40 and TIM-3, OX40 and PD-Ll, OX40 and BTLA, 4-lBB and PD-1, 4-lBB and CTLA-4, 4-lBB and LAG-3, 4-lBB and TIM-3, 4-lBB and PD-Ll, TIGIT and 4-lBB and 4-lBB and BTLA.
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the ABD
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the Central-Fv format shown in Figure 2.
- the format relies on the use of an inserted Fv domain thus forming an "extra" third antigen binding domain, wherein the Fab portions of the two monomers bind one receptor and the "extra" central-Fv domain binds another (generally the costimulatory receptor).
- the Fv domain is inserted between the Fc domain and the CHl-Fv region of the monomers, thus providing a third antigen binding domain, wherein each monomer contains a component of the Fv (e.g. one monomer comprises a variable heavy domain and the other a variable light domain of the "extra" central Fv domain).
- one monomer comprises a first heavy chain comprising a first variable heavy domain, a CHI domain, and Fc domain and an additional variable light domain.
- the additional variable light domain is covalently attached between the C- terminus of the CHI domain of the heavy constant domain and the N-terminus of the first Fc domain using domain linkers (vhl -CHI -[optional linker] -vl2-hinge-CH2-CH3).
- the other monomer comprises a first heavy chain comprising a first variable heavy domain, a CHI domain and Fc domain and an additional variable heavy domain (vhl -CHI- [optional linker] -vh2-hinge-CH2-CH3).
- the additional variable heavy domain domain is covalently attached between the C-terminus of the CHI domain of the heavy constant domain and the N-terminus of the first Fc domain using domain linkers.
- This embodiment utilizes a common light chain comprising a variable light domain and a constant light domain, that associates with the heavy chains to form two identical Fabs that each bind a receptor.
- the additional variable heavy domain and additional variable light domain form an "extra" central Fv that binds a second receptor.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, "extra" central Fv second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BTLA, TIGIT X OX40, PD-1 X OX40, PD-Ll X OX TIM-3, OX40 X BTLA,
- the Fc domains of the central-Fv format generally comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/K370S; L368D/ 370S : S364K; L368E/ 370S : S364K; T411T/E360E/Q362E : D401K; L368D/K370S : S364K E357L, K370S : S364K/E357Q, T366S/L368A/Y407V : T366W and
- skew variants e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/K370S; L368D/ 370S : S364K; L
- T366S L368A/Y407V/Y349C T366W/S354C
- optionally ablation variants including those shown in Figure 6
- optionally charged scFv linkers including those shown in Figure 8
- the heavy chain comprises pi variants (including those shown in Figure 5).
- the central-Fv format includes skew variants, pi variants, and ablation variants.
- some embodiments include central scFv formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor; b) a second monomer that comprises the skew variants L368D/ 370S, the pi variants N208D/Q295E/N384D/ Q418E/N421D, the ablation variants
- E233P/L234V/L235A/G236del/S267K and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the second receptor as outlined herein; and c) a light chain comprising a first variable light domain and a constant light domain.
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- the central-Fv format includes skew variants, pi variants, ablation variants and FcRn variants.
- some embodiments include central-scFv formats that comprise: a) a first monomer that comprises the skew variants S364K E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first receptor and an scFv domain that binds to a second receptor; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, PD-1 X ICOS, ICOS X PD-L1, PD-L1 X ICOS, ICOS X CTLA-4 and CTLA-4 X ICOS.
- Fvs that bind ICOS include, but are not limited to, shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193-27335, 28549-28556 and 28557-28665.
- suitable Fvs that bind PD-L1 include, but are not limited to, those shown in Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- suitable Fvs that bind GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- Fvs that bind OX40 include, but are not limited to, Figure 17, Figure 72 and Figure 73 and those listed in SEQ ID NO: 26272-26281.
- Fvs that bind 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- Fvs that bind PD-Ll include, but are not limited to, those of Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the one armed central-scFv format shown in Figure 1C.
- one monomer comprises just an Fc domain, while the other monomer includes a Fab domain (a first antigen binding domain), a scFv domain (a second antigen binding domain) and an Fc domain, where the scFv domain is inserted between the Fc domain and the Fc domain.
- the Fab portion binds one receptor target and the scFv binds another.
- one monomer comprises a first heavy chain comprising a first variable heavy domain, a CHI domain and Fc domain, with a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain.
- the scFv is covalently attached between the C-terminus of the CHI domain of the heavy constant domain and the N-terminus of the first Fc domain using domain linkers, in either orientation, VHl-CHl-[optional domain linker] -VH2-scFv linker- VL2- [optional domain linker]-CH2-CH3 or VHl-CHl-[optional domain linker]-VL2-scFv linker- VH2- [optional domain linker] -CH2-CH3.
- the second monomer comprises an Fc domain (CH2-CH3).
- This embodiment further utilizes a light chain comprising a variable light domain and a constant light domain, that associates with the heavy chain to form a Fab.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 ICOS, OX40 ICOS
- the Fc domains of the one armed central-scFv format generally comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K E357Q : L368D/ 370S; L368D/K370S : S364K; L368E/K370S : S364K; T411T/E360E/Q362E : D401K; L368D/ 370S : S364K/E357L, K370S : S364K/E357Q, T366S/L368A/Y407V : T366W and T366S L368A/Y407V/Y349C : T366W/S354C), optionally ablation variants (including those shown in Figure 6), optionally charged scFv linkers (including those shown in Figure 8) and the heavy
- the one armed central-scFv format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and a variable heavy domain that, with the variable light domain of the light chain, makes up an Fv that binds to a first receptor, and a scFv that binds to the other receptor; b) a second monomer that comprises the skew variants L368D/ 370S, the pi variants Q295E/N384D/Q418E/N421D, the ablation variants E233P/L234V/L235A/ G236del/S267K, and c) a light chain comprising a first variable light domain and a constant light domain.
- a first monomer that comprises the
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- the one armed central-scFv format includes skew variants, pi variants, ablation variants and FcRn variants. Accordingly, some embodiments include formats that comprise: a) a first monomer that comprises the skew variants
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the one armed scFv-mAb format shown in Figure 2D.
- one monomer comprises just an Fc domain, while the other monomer uses a scFv domain attached at the N-terminus of the heavy chain, generally through the use of a linker: vhl-scFv linker-vll- [optional domain linker]-VH2-CHl-hinge-CH2-CH3 or (in the opposite orientation) vll-scFv linker-vhl- [optional domain Uriker]-VH2-CHl-hinge-CH2-CH3.
- either the Fab portion binds one receptor target and the scFv binds another.
- This embodiment further utilizes a light chain comprising a variable light domain and a constant light domain, that associates with the heavy chain to form a Fab.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, ICOS X PD-L1, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-L1 X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-L1, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BTLA, TIGIT X OX40, PD-1 X OX40, PD-Ll X OX40, CTLA-4 X OX40, L
- the Fc domains of the comprise skew variants (e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/ 370S; L368D/K370S : S364K;
- skew variants e.g. a set of amino acid substitutions as shown in Figure 4, with particularly useful skew variants being selected from the group consisting of S364K/E357Q : L368D/ 370S; L368D/K370S : S364K;
- L368E/ 370S S364K; T411T E360E/Q362E : D401K; L368D/K370S : S364K E357L, K370S : S364K E357Q, T366S/L368A/Y407V : T366W and T366S/L368A Y407V Y349C :
- T366W/S354C optionally ablation variants (including those shown in Figure 6), optionally charged scFv linkers (including those shown in Figure 8) and the heavy chain comprises pi variants (including those shown in Figure 5).
- the one armed scFv-mAb format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first checkpoint inhibitor, and a second variable heavy domain; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- the one armed scFv-mAb format includes skew variants, pi variants, ablation variants and FcRn variants.
- some embodiments include bottle opener formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first checkpoint inhibitor, and a second variable heavy domain; b) a second monomer that comprises the skew variants L368D/ 370S, the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants E233P/L234V/L235A/G236del/S267K,
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- One heterodimeric scaffold that finds particular use in the present invention is the mAb-scFv format shown in Figure 2E.
- the format relies on the use of a N-terminal attachment of a scFv to one of the monomers, thus forming a third antigen binding domain, wherein the Fab portions of the two monomers each bind one target and the "extra" scFv domain binds a different target.
- the first monomer comprises a first heavy chain
- the second monomer comprises a heavy chain VH20CHl-hinge-CH2-CH3.
- This embodiment further utilizes a common light chain comprising a variable light domain and a constant light domain, that associates with the heavy chains to form two identical Fabs that bind one of the target antigens.
- these constructs include skew variants, pi variants, ablation variants, additional Fc variants, etc. as desired and described herein.
- suitable Fv pairs include (Fabs listed first, scFvs second) ICOS X PD-1, ICOS X PD-Ll, ICOS X CTLA-4, ICOS X LAG-3, ICOS X TIM-3, ICOS X BTLA, ICOS X TIGIT, TIGIT X ICOS, PD-1 X ICOS, PD-Ll X ICOS, CTLA-4 X ICOS, LAG-3 X ICOS, TIM-3 X ICOS, BTLA X ICOS, OX40 X TIGIT, OX40 X PD-1, OX40 X PD-Ll, OX40 X CTLA-4, OX40 X LAG-3, OX40 X TIM-3, OX40 X BTLA, TIGIT X OX40, PD-1 X OX40, PD-Ll X OX TIM-3, OX40 X BTLA,
- the Fc domains of the scFv-mAb format comprise skew variants
- T366S L368A/Y407V/Y349C T366W/S354C
- optionally ablation variants including those shown in Figure 6
- optionally charged scFv linkers including those shown in Figure 8
- the heavy chain comprises pi variants (including those shown in Figure 5).
- the mAb-scFv format includes skew variants, pi variants, and ablation variants.
- some embodiments include bottle opener formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P L234V/L235A/G236del/S267K, and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first checkpoint inhibitor, and a second variable heavy domain; b) a second monomer that comprises the skew variants L368D/K370S, the pi variants N208D/Q295E/N384D/
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- the mAb-scFv format includes skew variants, pi variants, ablation variants and FcRn variants.
- some embodiments include bottle opener formats that comprise: a) a first monomer that comprises the skew variants S364K E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain of the light chain, makes up an Fv that binds to a first checkpoint inhibitor, and a second variable heavy domain; b) a second monomer that comprises the skew variants
- L368D/ 370S the pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants E233P/L234V/L235A/G236del/S267K, the FcRn variants M428L/N434S and a first variable heavy domain that, with the first variable light domain, makes up the Fv that binds to the first checkpoint inhibitor as outlined herein, and a second variable light chain, that together with the second variable heavy chain forms an Fv (ABD) that binds a second checkpoint inhibitors; and c) a light chain comprising a first variable light domain and a constant light domain.
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- the present invention also provides dual scFv formats as are known in the art and shown in Figure 2B.
- the heterodimeric bispedfic antibody is made up of two scFv-Fc monomers (both in either (vh-scFv linker- vl- [optional domain linker]- CH2-CH3) format or (vl-scFv linker- vh- [optional domain linker] -CH2-CH3) format, or with one monomer in one orientation and the other in the other orientation.
- all ABDs are in the scFv format, with any combination of ICOS and PD-1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-Ll, ICOS and BTLA, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-Ll, GITR and BTLA, OX40 and PD-1, OX40 and CTLA-4, OX40 and LAG-3, OX40 and TIM-3, OX40 and PD-Ll, OX40 and BTLA, 4-lBB and PD-1, 4-lBB and CTLA-4, 4-lBB and LAG-3, 4-lBB and TIM-3, 4-lBB and PD-Ll and 4-lBB and BTLA being useful.
- the ABD sequences for these combinations can be as disclosed in the sequence listing or as shown in the Figures.
- the Fc domains of the dual scFv format comprise skew variants
- T366S L368A/Y407V/Y349C T366W/S354C
- optionally ablation variants including those shown in Figure 6
- optionally charged scFv linkers including those shown in Figure 8
- the heavy chain comprises pi variants (including those shown in Figure 5).
- the dual scFv format includes skew variants, pi variants, and ablation variants. Accordingly, some embodiments include formats that comprise: a) a first monomer that comprises the skew variants S364K/E357Q, the ablation variants E233P/L234V/L235A/G236del/S267K, and a scFv that binds a first receptor (VH1- scFv linker- VL1- [optional domain linker] -CH2-CH3 or VLl-scFv linker- VH1- [optional domain linker] -CH2-CH3) and b) a first monomer that comprises the skew variants
- the format comprises a ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the ABD
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and an Fv binds to GITR;
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fv binds to OX40;
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the ABD binds to ICOS;
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and an ABD binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind OX40 include, but are not limited to,
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- the Fv sequences outlined herein can also be used in both monospecific antibodies (e.g. "traditional monoclonal antibodies”) or non-heterodimeric bispecific formats (see Figure 2J, K and L).
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- Suitable non-heterodimeric bispecific formats are known in the art, and include a number of different formats as generally depicted in Spiess et al., Molecular Immunology (67):95-106 (2015) and Kontermann, mAbs 4:2, 182-197 (2012), both of which are expressly incorporated by reference and in particular for the figures, legends and citations to the formats therein.
- the bispecific antibody is in a "Dual Variable Domain-
- DVD-IgTM “DVD-IgTM” format (see Figure 2L) such as is generally described in US Patent No. 7,612,181, hereby expressly incorporated by reference in its entirety, and in particular for the Figures and Legends therein.
- the antibody is tetravalent and bispecific, and comprises 4 chains: two homodimeric heavy chains and two identical light chains.
- the heavy chains each have a VHl-(optional Hriker)-VH2-CHl-hinge-CH2-CH3 structure and the two light chains each have a VLl-optional linker-VL2-CL structure, with VHl and VLl forming a first ABD and the VH2 and VL2 forming a second ABD, where the first and second ABDs bind a costimulatory and a checkpoint receptor.
- suitable combinations include ICOS and PD-1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-Ll, ICOS and BTLA, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-Ll, GITR and BTLA, OX40 and PD-1, OX40 and CTLA-4, OX40 and LAG-3, OX40 and TIM-3, OX40 and PD-Ll, OX40 and BTLA, 4-lBB and PD-1, 4-lBB and CTLA-4, 4-lBB and LAG-3, 4-lBB and TIM-3, 4-lBB and PD-Ll and 4-lBB and BTLA.
- the DVD-IgTM and Central-scFv2 are two formats that are bispecific and tetravalent, and thus do not bind a costimulatory receptor in a monovalent fashion.
- the format comprises the ABD of [ICOS] H0.66_L0;
- the format comprises an ICOS ABD of H0.66_L0 combined with the ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the ABD
- ABD 7G8_H.303_L1.34 that binds to LAG-3; [00514] (5) the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and an ABD that binds to GITR;
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and and ABD that binds to OX40;
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and an ABD that binds to ICOS;
- the format comprises the ABD 1G6_L1.194_H1.279 that binds to PD-1 and an ABD that binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- the bispecific antibodies of the invention are in the
- Trident format as generally described in WO2015/184203, hereby expressly incorporated by reference in its entirety and in particular for the Figures, Legends, definitions and sequences of "Heterodimer-Promoting Domains" or "HPDs", including “K-coil” and “E- coil” sequences. Tridents rely on using two different HPDs that associate to form a heterodimeric structure as a component of the structure, see Figure 2M.
- the Trident format include a "traditional" heavy and light chain (e.g.
- VHl-CHl-hinge-CH2- CH3 and VL1-CL a third chain comprising a first "diabody-type binding domain" or "DART®”, VH2-(linker)-VL3-HPDl and a fourth chain comprising a second DART®, VH3- (linker)-(lmker)-VL2-HPD2.
- the VH1 and VL1 form a first ABD
- the VH2 and VL2 form a second ABD
- the VH3 and VL3 form a third ABD.
- the second and third ABDs bind the same antigen, in this instance generally the checkpoint receptor, e.g.
- suitable combinations include ICOS and PD-1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-L1, ICOS and BTLA, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-L1, GITR and BTLA, OX40 and PD-1, OX40 and CTLA-4, OX40 and LAG-3, OX40 and TIM-3, OX40 and PD-L1, OX40 and BTLA, 4-1BB and PD-1, 4-1BB and CTLA-4, 4-1BB and LAG-3, 4-1BB and TIM-3, 4-1BB and PD-L1 and 4-1BB and BTLA.
- the format comprises a Fab ABD binds to ICOS that has the ABD of [ICOS]
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv
- ABD comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1;
- the format comprises an ICOS ABD of H0.66_L0 combined with the scFv comprising the ABD H3.23_L0.129 that binds to CTLA-4;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to GITR;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to OX40;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to ICOS;
- the format comprises a scFv comprising the ABD 1G6_L1.194_H1.279 that binds to PD-1 and the Fab binds to 4-1BB;
- the format comprises the ABD of H0.66_L0 that binds to ICOS and an
- ABD that binds to PD-L1.
- specific ABDs that bind human ICOS include, but are not limited to, [ICOS]_H0L0 and [ICOS]H0.66_L0 and and those shown in Figure 19, Figure 20, Figure 24, Figure 68 and Figure 77 as well as SEQ ID NO: 27869-28086, 28087-28269, 27193- 27335, 28549-28556 and 28557-28665.
- specific ABDs that bind human GITR include, but are not limited to, those in Figure 18, Figure 72 and Figure 73 and those listed in SEQ ID NO:26282- 26290.
- specific ABDs that bind human 4-1BB include, but are not limited to, Figure 16, Figure 72 and Figure 73 and SEQ ID NO: 26262-2671.
- specific ABDs that bind human PD-L1 include, but are not limited to, Figure 15, Figure 73 and Figure 78 and SEQ ID NO: 3961-4432.
- the novel Fv sequences outlined herein can also be used in both monospecific antibodies (e.g. "traditional monoclonal antibodies”) or non-heterodimeric bispecific formats. Accordingly, the present invention provides monoclonal (monospecific) antibodies comprising the 6 CDRs and/or the vh and vl sequences from the figures, generally with IgGl, IgG2, IgG3 or IgG4 constant regions, with IgGl , IgG2 and IgG4 (including IgG4 constant regions comprising a S228P amino acid substitution) finding particular use in some embodiments. That is, any sequence herein with a "H_L" designation can be linked to the constant region of a human IgGl antibody. VIII. Antigen Binding Domains (ABDs) to Target Antigens
- the bispecific antibodies of the invention have two different antigen binding domains (ABDs) that bind to two different target receptor antigens ("target pairs"), in either bivalent, bispecific formats or trivalent, bispecific formats as generally shown in Figure 2.
- ABSDs antigen binding domains
- target pairs two different target receptor antigens
- the bispecific antibodies bind to a first target antigen comprising a checkpoint receptor and a second target antigen comprising a costimulatory receptor.
- Suitable checkpoint receptors as outlined herein include PD-1, PD-L1, LAG-3, TIM-3, CTLA- 4, BTLA and TIGIT.
- Suitable costimulatory receptors as outlined herein include ICOS, GITR, OX40 and 4-1BB.
- Suitable target checkpoint antigens include human (and sometimes cyno) PD-
- suitable bispecific antibodies bind ICOS and PD-1, ICOS and CTLA-4, ICOS and LAG-3, ICOS and TIM-3, ICOS and PD-L1, ICOS and BTLA, ICOS and TIGIT, GITR and TIGIT, GITR and PD-1, GITR and CTLA-4, GITR and LAG-3, GITR and TIM-3, GITR and PD-L1, GITR and BTLA, OX40 and PD-1, OX40 and TIGIT, OX40 and CTLA-4, IC OX40 OS and LAG-3, OX40 and TIM-3, OX40 and PD-L1, OX40 and BTLA, 4-1BB and PD-1, 4-1BB and CTLA-4, 4-1BB and LAG-3, 4-1BB and TIM-3, 4-1BB and PD-L1, OX40 and BTLA, 4-1BB and PD-1, 4-1BB and CTLA-4, 4-1BB and LAG-3, 4
- bispecific antibodies are named "anti-PD-1 X anti-
- CTLA-4 or generally simplistically or for ease (and thus interchangeably) as "PD-1 X CTLA-4", etc. for each pair.
- the order of the antigen list in the name does not confer structure; that is a PD-1 X CTLA-4 bottle opener antibody can have the scFv bind to PD-1 or CTLA-4, although in some cases, the order specifies structure as indicated.
- these combinations of ABDs can be in a variety of formats, as outlined below, generally in combinations where one ABD is in a Fab format and the other is in an scFv format. As discussed herein and shown in Figure 2, some formats use a single Fab and a single scFv (A, C and D), and some formats use two Fabs and a single scFv (E, F, G, H and I).
- Figure 1 presents expression data (RNAseq V2 RSEM) of PD-1 and T cell costimulatory receptors for bladder, breast, colon, head & neck, kidney, lung-adeno, lung squamous, ovarian, pancreatic, prostate, and melanoma cancer compiled from The Cancer Genome Atlas (TCGA). The square of the Pearson correlation coefficient was calculated for PD-1 against T cell costimulatory receptors.
- Figure 2A to O depict several formats for the bispecific antibodies of the present invention.
- the first is the "bottle opener” format, with a first and a second anti- antigen binding domain.
- mAb-Fv, mAb-scFv, Central-scFv, Central-Fv, one armed central-scFv, one scFv-mAb, scFv-mAb dual scFv format are all shown.
- Figure 2J depicts the "central-scFv2" format, with two Fab-scFv arms, wherein the Fabs bind a first antigen and the scFvs bind a second antigen.
- Figure 2K depicts the bispecific mAb format, with a first Fab arm binding a first antigen and a second Fab arm binding a second antigen.
- Figure 2L depicts the DVD-IgG format (see, e.g., U.S. Patent No. 7,612,181, hereby expressly incorporated by reference and as discussed below).
- Figure 2M depicts the Trident format (see, e.g., WO 2015/184203, hereby expressly incorporated by reference and as discussed below).
- the scFv domains depicted they can be either N- to C-terminus variable heavy-(optional linker)-variable light, or the opposite.
- the scFv can be attached either to the N-terminus of a heavy chain monomer or to the N-terminus of the light chain.
- Figure 3 depicts the sequences of XENP23104, a bottle opener format with the
- ICOS as the Fab side ([ICOS]_H0.66_L0) and the PD-1 as the scFv (1G6_L1.94_H1.279), and includes the M428L/434S variant to extend serum half life.
- the CDRs are underlined, the scFv linker is double underlined (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker, although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- the naming convention illustrates the orientation of the scFv from N- to C- terminus; some of the sequences herein are oriented as VH-scFv linker- VL (from N- to C- terminus), while some are oriented as VL-scFv linker- VH (from N- to C-terminus), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- Figure 4A to E depict useful pairs of heterodimerization variant sets
- Figure 5 depict a list of isosteric variant antibody constant regions and their respective substitutions.
- pl_(-) indicates lower pi variants, while pl_(+) indicates higher pi variants.
- heterodimerization variants of the invention (and other variant types as well, as outlined herein).
- Figure 6 depict useful ablation variants that ablate FcyR binding (sometimes referred to as “knock outs” or “KO” variants). Generally, ablation variants are found on both monomers, although in some cases they may be on only one monomer.
- Figure 7 show two particularly useful embodiments of the invention. The
- Non-Fv components of this embodiment is shown in Figure 9 A, although the other formats of Figure 9 can be used as well.
- Figure 8A and B depict a number of charged scFv linkers that find use in increasing or decreasing the pi of heterodimeric antibodies that utilize one or more scFv as a component.
- the (+H) positive linker finds particular use herein.
- a single prior art scFv linker with single charge is references as "Whitlow", from Whitlow et al., Protein
- Figure 9 shows the sequences of several useful bottle opener format backbones based on human IgGl, without the Fv sequences (e.g. the scFv and the vh and vl for the Fab side).
- Bottle opener backbone 1 is based on human IgGl (356E/358M allotype), and includes the S364K/E357Q : L368D/K370S skew variants, the
- Bottle opener backbone 2 is based on human IgGl (356E/358M allotype), and includes different skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 3 is based on human IgGl (356E/358M allotype), and includes different skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 4 is based on human IgGl (356E/358M allotype), and includes different skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 5 is based on human IgGl (356D/358L allotype), and includes the S364K/E357Q : L368D/ 370S skew variants, the N208D/Q295E/ 384D/Q418E/N421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Bottle opener backbone 6 is based on human IgGl (356E/358M allotype), and includes the
- Bottle opener backbone 7 is identical to 6 except the mutation is N297S.
- Alternative formats for bottle opener backbones 6 and 7 can exclude the ablation variants E233P L234V/L235A/G236del/S267K in both chains.
- Backbone 8 is based on human IgG4, and includes the S364K/E357Q : L368D/K370S skew variants, the N208D/Q295E/ 384D/Q418E/N421D pi variants on the Fab side and the
- Alternative formats for bottle opener backbone 8 can exclude the ablation variants E233P/L234V/L235A/G236del/S267K in both chains
- Backbone 9 is based on human IgG2, and includes the S364K E357Q : L368D/K370S skew variants, the
- Backbone 10 is based on human IgG2, and includes the S364K E357Q : L368D/K370S skew variants, the
- these sequences can be used with any vh and vl pairs outlined herein, with one monomer including a scFv (optionally including a charged scFv linker) and the other monomer including the Fab sequences (e.g. a vh attached to the "Fab side heavy chain” and a vl attached to the "constant light chain”).
- any Fv sequences outlined herein for anti- CTLA-4, anti-PD-1, anti-LAG-3, anti-TIM-3, anti-TIGIT and anti-BTLA, whether as scFv (again, optionally with charged scFv linkers) or as Fabs, can be incorporated into these Figure 37 backbones in any combination.
- the constant light chain depicted in Figure 9A can be used for all of the constructs in the figure, although the kappa constant light chain can also be substituted.
- bottle opener backbones find use in the Central- scFv format of Figure IF, where an additional, second Fab (vh-CHl and vl-constant light) with the same antigen binding as the first Fab is added to the N-terminus of the scFv on the "bottle opener side".
- sequences that are 90, 95, 98 and
- the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition to the skew, pi and ablation variants contained within the backbones of this figure.
- Figure 10 depicts the sequences for a select number of anti-PD-1 antibodies. It is important to note that these sequences were generated based on human IgGl, with an ablation variant (E233P/L234V L235A/G236del/S267K, "IgGl_PVA JS267K") which is depicted in Figure 6A.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 11 depict a select number of PD-1 ABDs, with additional anti-PD-1
- ABDs being listed as SEQ 1-2392, 3125-3144, 4697-7594 and 4697-21810.
- the CDRs are underlined, the scFv linker is double underlines (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C-terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus), while some are oriented as VL-scFv linker- VH (from N- to C- terminus), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- Figure 12 depict a select number of CTLA-4 ABDs, with additional anti-
- CTLA-4 ABDs being listed as SEQ ID NO:2393-2414 and 3737-3816.
- the CDRs are underlined, the scFv linker is double underlines (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C-terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus), while some are oriented as VL-scFv linker- VH (from N- to C- terminus), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- Figure 13 depict a select number of LAG-3 ABDs, with additional anti-LAG-3
- ABDs being listed as SEQ ID NO:2415-2604 and 3817-3960.
- the CDRs are underlined, the scFv linker is double underlines (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker (SEQ ID NO: XXX), although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure 8), and the slashes indicate the border(s) of the variable domains>
- the naming convention illustrates the orientation of the scFv from N- to C-terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus), while some are oriented as VL-scFv linker- VH (from N- to C- terminus), although as will be appreciated by those in the art, these sequences may also be
- Figure 14 depicts the sequences for a select number of anti-TIM-3 antibodies.
- Figure 15 depicts the sequences for a select number of anti-PD-Ll antibodies.
- Figure 16 depicts the sequences for a prototype anti-4-lBB antibody. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P L234V L235A/G236del/S267K, "IgGl_PVA JS267K”), although the other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 17 depicts the sequences for a prototype anti-OX40 antibody. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P L234V L235A/G236del/S267K, "IgGl_PVA JS267K”), although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 18 depicts the sequences for a prototype anti-GITR antibody. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P L234V L235A/G236del/S267K, "IgGl_PVA JS267K”), although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 1, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 19 depicts the sequences for prototype anti-ICOS antibodies. It is important to note that these sequences were generated based on human IgGl backbone, with an ablation variant (E233P L234V L235A/G236del/S267K, "IgGl_PVA JS267K”), although other formats can be used as well.
- the CDRs are underlined. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table X, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- Figure 20 depicts sequences for exemplary anti-ICOS Fabs.
- the CDRs are underlined and slashes (/) indicate the border(s) of the variable regions.
- the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table X, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems.
- these VH and VL sequences can be used either in a scFv format or in a Fab format. It is important to note that these sequences were generated using six- histidine (His6 or HHHHHH) C-terminal tags at the C-terminus of the heavy chains, which have been removed.
- Figure 21 depicts melting temperatures (Tm) and changes in melting temperature from the parental Fab (XENP22050) as determined by DSF of variant anti-ICOS Fabs engineered for stability.
- Figure 22 depicts equilibrium dissociation constants (KD), association rates
- Figure 23 depicts equilibrium dissociation constants (KD), association rates
- Figure 24 depicts sequences for exemplary anti-ICOS scFvs.
- the CDRs are underlined, the scFv linker is double underline (in the sequences, the scFv linker is a positively charged scFv (GKPGS)4 linker, although as will be appreciated by those in the art, this linker can be replaced by other linkers, including uncharged or negatively charged linkers, some of which are depicted in Figure X), and slashes (/) indicate the border(s) of the variable regions.
- GKPGS positively charged scFv
- the naming convention illustrates the orientation of the scFv from N- to C- terminus; some of the sequences in this Figure are oriented as VH-scFv linker- VL (from N- to C-terminus, see Figure 24), while some are oriented as VL-scFv linker-VH (from N- to C- terminus, see Figure 24B), although as will be appreciated by those in the art, these sequences may also be used in the opposition orientation from their depiction herein.
- VH and VL sequences can be used either in a scFv format or in a Fab format. It is important to note that these sequences were generated using polyhistidine (His6 or HHHHHH) C-terminal tags at the C-terminus of the heavy chains, which have been removed.
- Figure 25 depicts melting temperatures (Tm) and changes in melting temperature from the parental scFv (XENP24352; oriented as VH-scFv linker- VL from N- to C-terminus) as determined by DSF of variant anti-ICOS scFvs engineered for stability.
- Figure 26 depicts the amino acid sequences of prototype anti-costim x anti- checkpoint antibodies in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 27 depicts induction of cytokine secretion by prototype
- Figure 28 depicts induction of IL-2 secretion in naive (non-SEB stimulated) and SEB-stimulated PBMCs following treatment with the indicated test articles.
- Figure 29 depicts a schematic associated with the benefit of a costim x checkpoint blockade bispecific antibody, showing that because tumor TILs co-express immune checkpoint receptors and costimulatory receptors, a bispecific antibody increases specificity, enhancing anti-tumor activity and avoiding peripheral toxicity.
- Figure 30 depicts that double-positive cells are selectively occupied by exemplary anti-ICOS x anti-PD-1 antibody (XENP20896) as compared to one-arm anti-PD-1 antibody (XENP20111) and one-arm anti-ICOS antibody (XENP20266).
- Figure 31 shows the receptor occupancy of anti-ICOS x anti-PD-1 bispecific antibody (XENP20896), one-arm anti-ICOS antibody (XENP20266) and one-arm anti-PD-1 antibody (XENP20111) on A) PD-1 and ICOS double-positive T cells and B) PD-1 and ICOS double-negative T cells after SEB stimulation of human PBMCs.
- Figure 32 depicts the amino acid sequences of exemplary anti-ICOS x anti-
- PD-1 antibodies in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 33 depicts the amino acid sequences of exemplary anti-ICOS x anti-
- PD-1 antibodies in the bottle-opener format (Fab-scFv-Fc) which include the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- Figure 34 depicts equilibrium dissociation constants (KD), association rates
- Figure 35 depicts equilibrium dissociation constants (KD), association rates
- Figure 36 depicts cell surface binding of variant anti-ICOS x anti-PD-1 bispecific to human T cells in SEB-stimulated PBMC assays in two separate experiments depicted in A) and B).
- Figure 37 shows the receptor occupancy of variant anti-ICOS x anti-PD-1 bispecific antibodies, one-arm anti-ICOS antibodies and one-arm anti-PD-1 antibody (XENP20111) on PD-1 and ICOS double-positive T cells after SEB stimulation of human PBMCs.
- Figure 38 show that variant anti-ICOS x anti-PD-1 bispecific antibodies promote A) IL-2 and B) IFNy secretion from SEB stimulated PBMCs.
- Figure 39 show that variant anti-ICOS x anti-PD-1 bispecific antibodies promote A) IL-2 and B) IFNy secretion from SEB-stimulated PBMCs.
- Figure 40 depicts the concentration of IFNy in mice on Day A) 7 and B) 11 after engraf tment with human PBMCs and treatment with the indicated test articles.
- Figure 41 depicts CD45+ cell counts in mice as determined by flow cytometry on Day A) 11 and B)14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 42 depicts A) CD8+ T cell and B) CD4+ T cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles (**p ⁇ 0.01).
- Figure 43 depicts the change in body weight in mice by Day 14 after engraftment with human PBMCs and treatment with the indicated test articles (**p ⁇ 0.01).
- Figure 44 depicts the concentration of IFNy in mice on Day A) 7 and B) 14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 45 depicts CD45+ cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 46 depicts A) CD8+ T cell and B) CD4+ T cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test articles.”
- Figure 47 depicts the change in body weight in mice by Day 12 and 15 after engraftment with human PBMCs and treatment with the indicated test articles.
- Figure 48 depicts the amino acid sequences of exemplary anti-ICOS x anti-
- PD-1 antibodies in the bottle-opener format (Fab-scFv-Fc) with alternative ICOS ABDs.
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 49 depict cytokine release assay for IL-2 after SEB-stimulation of human PBMCs and treatment with alternative anti-ICOS x anti-PD-1 bispedfic antibodies.
- Figure 50 depict cytokine release assay for IL-2 (as fold induction over bivalent anti-RSV mAb) after SEB-stimulation of human PBMCs and treatment with alternative anti-ICOS x anti-PD-1 bispedfic antibodies.
- Figure 51 depicts AKT phosphorylation in SEB-stimulated purified CD3+ T cells after treatment with anti-ICOS x anti-PD-1 bispedfic antibodies.
- Figure 52 depicts fold induction of A) IL-17A, B) IL17F, C) IL-22, D) IL-10, E)
- Figure 53 depict mean fold induction in expression of selected immune response genes by indicated test articles over treatment with bivalent anti-RSV mAb as determined by NanoString.
- the shading intensity corresponds to the magnitude of the fold change.
- Figure 54 depicts CD45+ cell counts in mice as determined by flow cytometry on Day 14 after engraftment with human PBMCs and treatment with the indicated test artides.
- Figure 55 similar to Figure 9 and Figure 75, depicts the sequences of the
- backbone portion (e.g. without the Fvs) of a number of additional formats, induding the Central scFv of Figure 2F, the Central-scFv2 format of Figure 2J, the bispedfic mAb of Figure 2K, the DVD-Ig of Figure 2L and the Trident format of Figure 2M.
- the DVD- Ig® linkers are shown with double underlining, with other linkers found in WO2007/024715, hereby incorporated by reference in its entirety and in particular for those sequences.
- Trident linkers and coil-coil sequences are shown in WO 2015/184203, hereby incorporated by reference in its entirety and in particular for those sequences.
- Figure 56 depicts the amino acid sequence of illustrative anti-PD-1 x anti-
- ICOS antibodies in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 57 depicts the amino acid sequence of illustrative anti-PD-1 x anti-
- ICOS antibodies in the central-scFv format.
- the antibodies are named using the first Fab-Fc variable region first and the Fab-scFv-Fc variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, Fab-scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border (s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 58 depicts the amino acid sequence of illustrative anti-PD-1 x anti-
- ICOS antibodies in the central-scFv2 format.
- the antibodies are named using the Fab variable region first and the scFv variable region second, followed by the chain designation (heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker-VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 59 depicts the amino acid sequence of an illustrative anti-PD-1 x anti-
- ICOS antibody in the bispecific mAb format.
- the antibodies are named using the first Fab variable region for a first antigen and the second Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain 1 or Light Chain 1 for the first antigen and Heavy Chain 2 or Light Chain 2 for the second antigen).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/ 434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 60 depicts the amino acid sequence of an illustrative anti-PD-1 x anti-
- ICOS antibody in the DVD-IgG format.
- the antibodies are named using the first variable region for a first antigen and the second Fab variable region for a second antigen, followed by the chain designation (Heavy Chain or Light Chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/ 434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 61 depicts the amino acid sequence of an illustrative anti-PD-1 x anti-
- ICOS antibody in the Trident format.
- the antibodies are named using the VL and VH of a first antigen which comprises a DART and the Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain or Light Chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 62 depicts induction of cytokine secretion (IL-2) by alternative format costim x checkpoint blockade bispecific antibodies in an SEB-stimulated PBMC assay.
- Figure 63 depicts the amino acid sequences of an illustrative anti-ICOS x anti-
- CTLA-4 antibody in the bottle-opener format (Fab-scFv-Fc).
- the antibodies are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- the scFv domain has different orientations (N- to C-terminus) of either VH-scFv linker- VL or VL-scFv linker- VH as indicated, although this can be reversed.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 64 depicts the amino acid sequence of illustrative anti-LAG-3 x anti-
- ICOS antibodies in the bispecific mAb format.
- the antibodies are named using the first Fab variable region for a first antigen and the second Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain 1 or Light Chain 1 for the first antigen and Heavy Chain 2 or Light Chain 2 for the second antigen).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 65 depicts the amino acid sequence of an illustrative anti-TIM-3 x anti-
- ICOS antibody in the bispecific mAb format.
- the antibodies are named using the first Fab variable region for a first antigen and the second Fab variable region for a second antigen, separated by a dash, followed by the chain designation (Heavy Chain 1 or Light Chain 1 for the first antigen and Heavy Chain 2 or Light Chain 2 for the second antigen).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- Each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half -life in serum.
- Figure 66 depicts the amino acid sequences of anti-ICOS x anti-PD-Ll antibodies in the bottle-opener format (Fab-scFv-Fc) and central-scFv2 format.
- the bottle- openers are named using the Fab variable region first and the scFv variable region second, separated by a dash, followed by the chain designation (Fab-Fc heavy chain, scFv-Fc heavy chain or light chain).
- Central-scFv2s are named using the Fab variable region first and the scFv variable region second, followed by the chain designation (heavy chain or light chain).
- CDRs are underlined and slashes indicate the border(s) of the variable regions.
- each sequence outlined herein can include or exclude the M428L/N434S variants in one or preferably both Fc domains, which results in longer half-life in serum.
- Figure 67 depicts induction of cytokine secretion (IL-2) by additional costim x checkpoint blockade bispecific antibodies in an SEB-stimulated PBMC assay.
- Figure 68 depict amino acid sequences for exemplary one-arm anti-ICOS Fab-
- Fc antibodies are underlined and slashes indicate the border(s) of variable regions. These are referred to as "one-arm” or “one armed” formats as one amino acid chain is only an Fc domain, with the other side being an anti-ICOS Fab side.
- the Fc domain contains the S364K E357Q skew variants, as well as the pI(-)_Isosteric_A variants depicted in Figure X.
- the Fab Fc domain contains the L368D/K370S skew variants as well as the pi ISO(+RR) variants depicted in Figure X. Both Fc domains include the ablation variants
- Figure 69 depicts equilibrium dissociation constants (KD), association rates
- Figure 70 depicts AKT phosphorylation in SEB-stimulated purified CD3+ T cells after treatment with bivalent and monovalent anti-PD-1 antibodies and anti-ICOS x anti-PD-1 bispecific antibodies.
- Figure 71 depicts AKT phosphorylation in purified CD3+ T cells after treatment with monovalent anti-ICOS Fab-Fc antibodies with alternative anti-ICOS ABDs.
- Figure 72 depict some prototype bispecific antibodies (OX40 X PD-1, GITR X
- Figure 73 depict some prototype mAbs (4-1BB, OX40, GITR, ICOS, PD-L1 and PD-1), the Fvs of which can be used in combination with the other Fvs of the invention and in any format (bottle opener, mAb-Fv, mAb-scFv, central-scFv, bispecific mAb, central- Fv, one armed central-scFv, one armed scFv-mAb, dual scFv, DVD-Ig or Trident).
- Some additional ICOS X PD-L1 bottle opener sequences are shown as well.
- Figure 74 depict additional PD-1 X ICOS bottle openers, in some cases with the PD-1 Fv being in the Fab format and the ICOS Fv in a scFv format and in other cases reversed.
- Figure 75A to D shows the sequences of a mAb-scFv backbone of use in the invention, to which the Fv sequences of the invention are added.
- mAb-scFv backbone 1 is based on human IgGl (356E/358M allotype), and includes the S364K E357Q : L368D/K370S skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Backbone 2 is based on human IgGl (356D/358L allotype), and includes the S364K/E357Q : L368D/K370S skew variants, the N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
- Backbone 3 is based on human IgGl (356E/358M allotype), and includes the S364K E357Q : L368D/ 370S skew variants, N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side and the
- Backbone 4 is identical to 3 except the mutation is N297S.
- Backbone 5 is based on human IgG4, and includes the S364K/E357Q : L368D/K370S skew variants, the
- Backbone 6 is based on human IgG2, and includes the S364K E357Q : L368D/ 370S skew variants, the N208D/Q295E/N384D/Q418E/N421D pi variants on the Fab side.
- Backbone 7 is based on human IgG2, and includes the S364K/E357Q : L368D/ 370S skew variants, the N208D/Q295E/N384D/Q418E/ 421D pi variants on the Fab side as well as a S267K variant on both chains.
- these sequences can be used with any vh and vl pairs outlined herein, with one monomer including both a Fab and an scFv (optionally including a charged scFv linker) and the other monomer including the Fab sequence (e.g.
- the monomer 1 side is the Fab-scFv pi negative side, and includes the heterodimerization variants L368D/ 370S, the isosteric pi variants N208D/Q295E/N384D/Q418E/N421D, the ablation variants E233P/L234V/L235A/ G236del/S267K, (all relative to IgGl).
- the monomer 2 side is the scFv pi positive side, and includes the heterodimerization variants 364K E357Q.
- sequences that are 90, 95, 98 and
- Figure 76 depict a number of prior art sequences for Fvs that bind human PD-
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201901712YA SG11201901712YA (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN201780060900.7A CN110267990B (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3035343A CA3035343A1 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR1020197009280A KR102575681B1 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind to costimulatory and checkpoint receptors |
RU2019109147A RU2788521C2 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory receptors and checkpoint receptors |
EP17765002.5A EP3507306A1 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2019511464A JP7080219B2 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that link to co-stimulatory and checkpoint receptors |
MX2019002349A MX2019002349A (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors. |
AU2017321625A AU2017321625A1 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR1020237029969A KR20230130174A (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
ZA2019/01752A ZA201901752B (en) | 2016-08-30 | 2019-03-20 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2022084854A JP2022111148A (en) | 2016-08-30 | 2022-05-24 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662381239P | 2016-08-30 | 2016-08-30 | |
US62/381,239 | 2016-08-30 | ||
US201762456033P | 2017-02-07 | 2017-02-07 | |
US62/456,033 | 2017-02-07 | ||
US201762479723P | 2017-03-31 | 2017-03-31 | |
US62/479,723 | 2017-03-31 | ||
US15/623,314 | 2017-06-14 | ||
US15/623,314 US10787518B2 (en) | 2016-06-14 | 2017-06-14 | Bispecific checkpoint inhibitor antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018045110A1 true WO2018045110A1 (en) | 2018-03-08 |
Family
ID=59846700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/049497 WO2018045110A1 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018045110A1 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
WO2020010284A1 (en) * | 2018-07-04 | 2020-01-09 | Cytoimmune Therapeutics, LLC | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 |
WO2020018354A1 (en) | 2018-07-19 | 2020-01-23 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
US10604576B2 (en) | 2016-06-20 | 2020-03-31 | Kymab Limited | Antibodies and immunocytokines |
CN110964114A (en) * | 2018-09-29 | 2020-04-07 | 上海博槿生物科技有限公司 | Double-target antigen binding molecule |
WO2020107715A1 (en) * | 2018-11-30 | 2020-06-04 | Abl Bio Inc. | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
WO2020141974A1 (en) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
US10844119B2 (en) | 2016-10-11 | 2020-11-24 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021030488A1 (en) * | 2019-08-12 | 2021-02-18 | Bienvenue David Leonard | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
WO2021046289A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab |
WO2021091953A1 (en) * | 2019-11-05 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | N-terminal scfv multispecific binding molecules |
WO2021110935A1 (en) * | 2019-12-06 | 2021-06-10 | Oncoone Research & Development Gmbh | Anti-oxMIF/anti-CD3 BISPECIFIC ANTIBODY CONSTRUCTS |
US11098117B2 (en) | 2017-04-13 | 2021-08-24 | Agenus Inc. | Anti-CD137 antibodies and methods of use thereof |
JP2021521779A (en) * | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | A heterodimer fusion protein targeting LAG-3, including the IL-15 / IL-15RA Fc fusion protein and the LAG-3 antigen binding domain. |
JP2021524282A (en) * | 2018-05-17 | 2021-09-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Receptor inhibition by phosphatase mobilization |
WO2021209356A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
WO2021209357A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
WO2021209358A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein |
US20220153869A1 (en) * | 2020-11-16 | 2022-05-19 | Tavotek Biotherapeutics (Hong Kong) Limited | Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof |
WO2022140701A1 (en) | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains |
US11440960B2 (en) | 2017-06-20 | 2022-09-13 | Kymab Limited | TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo |
WO2023001987A2 (en) | 2021-07-22 | 2023-01-26 | University Of Dundee | Therapeutic muteins |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
WO2023064927A1 (en) * | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023064929A1 (en) * | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023109900A1 (en) * | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
US11685786B2 (en) | 2016-09-23 | 2023-06-27 | Merus N.V. | Binding molecules that bind CD137 and PD-L1 |
US11753479B2 (en) | 2014-03-04 | 2023-09-12 | Kymab Limited | Nucleic acids encoding anti-OX40L antibodies |
US11773176B2 (en) | 2020-01-24 | 2023-10-03 | Aprilbio Co., Ltd. | Multispecific antibodies, compositions comprising the same, and vectors and uses thereof |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
EP4041772A4 (en) * | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co Ltd | Antibodies binding 4-1bb and uses thereof |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011018A1 (en) | 1990-12-19 | 1992-07-09 | Protein Design Labs, Inc. | Improved humanized immunoglobulins |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6054297A (en) | 1991-06-14 | 2000-04-25 | Genentech, Inc. | Humanized antibodies and methods for making them |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
US20040214988A1 (en) | 2000-03-23 | 2004-10-28 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
WO2005035727A2 (en) | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Polymer derivatives |
WO2005074524A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US20090163699A1 (en) | 2004-11-12 | 2009-06-25 | Chamberlain Aaron Keith | Fc VARIANTS WITH ALTERED BINDING TO FcRn |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
US20120121597A1 (en) * | 2010-11-12 | 2012-05-17 | The Rockefeller University | Fusion proteins for hiv therapy |
US20120149876A1 (en) | 2010-11-05 | 2012-06-14 | Zymeworks Inc. | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain |
US8216805B2 (en) | 1995-03-01 | 2012-07-10 | Genentech, Inc. | Knobs and holes heteromeric polypeptides |
WO2013164694A1 (en) * | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
US20140056879A1 (en) * | 2004-11-12 | 2014-02-27 | Xencor, Inc. | Fc variants that extend antibody half-life |
WO2014145806A2 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins |
US20140288275A1 (en) | 2013-01-14 | 2014-09-25 | Xencor, Inc. | Novel heterodimeric proteins |
WO2014207064A1 (en) * | 2013-06-27 | 2014-12-31 | Alligator Bioscience Ab | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 |
WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US20150307629A1 (en) | 2014-03-28 | 2015-10-29 | Matthew Bernett | Bispecific antibodies that bind to CD38 and CD3 |
WO2015184203A1 (en) | 2014-05-29 | 2015-12-03 | Macrogenics, Inc. | Tri-specific binding molecules and methods of use thereof |
WO2016086196A2 (en) * | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
WO2016110584A1 (en) * | 2015-01-08 | 2016-07-14 | Biontech Ag | Agonistic tnf receptor binding agents |
WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
WO2016120789A1 (en) * | 2015-01-28 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Agonistic icos binding proteins |
US20160244525A1 (en) | 2014-11-05 | 2016-08-25 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
-
2017
- 2017-08-30 WO PCT/US2017/049497 patent/WO2018045110A1/en unknown
Patent Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693761A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Polynucleotides encoding improved humanized immunoglobulins |
US5693762A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6180370B1 (en) | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1992011018A1 (en) | 1990-12-19 | 1992-07-09 | Protein Design Labs, Inc. | Improved humanized immunoglobulins |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6054297A (en) | 1991-06-14 | 2000-04-25 | Genentech, Inc. | Humanized antibodies and methods for making them |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
US8216805B2 (en) | 1995-03-01 | 2012-07-10 | Genentech, Inc. | Knobs and holes heteromeric polypeptides |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US20040214988A1 (en) | 2000-03-23 | 2004-10-28 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
WO2005035727A2 (en) | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Polymer derivatives |
US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
WO2005074524A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
US20140056879A1 (en) * | 2004-11-12 | 2014-02-27 | Xencor, Inc. | Fc variants that extend antibody half-life |
US20090163699A1 (en) | 2004-11-12 | 2009-06-25 | Chamberlain Aaron Keith | Fc VARIANTS WITH ALTERED BINDING TO FcRn |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US20120149876A1 (en) | 2010-11-05 | 2012-06-14 | Zymeworks Inc. | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain |
US20120121597A1 (en) * | 2010-11-12 | 2012-05-17 | The Rockefeller University | Fusion proteins for hiv therapy |
WO2013164694A1 (en) * | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
US20140288275A1 (en) | 2013-01-14 | 2014-09-25 | Xencor, Inc. | Novel heterodimeric proteins |
US20140370013A1 (en) | 2013-01-14 | 2014-12-18 | Xencor, Inc. | Novel heterodimeric proteins |
WO2014145806A2 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins |
WO2014207064A1 (en) * | 2013-06-27 | 2014-12-31 | Alligator Bioscience Ab | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 |
WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US20150307629A1 (en) | 2014-03-28 | 2015-10-29 | Matthew Bernett | Bispecific antibodies that bind to CD38 and CD3 |
WO2015184203A1 (en) | 2014-05-29 | 2015-12-03 | Macrogenics, Inc. | Tri-specific binding molecules and methods of use thereof |
US20160244525A1 (en) | 2014-11-05 | 2016-08-25 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
WO2016086196A2 (en) * | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
WO2016110584A1 (en) * | 2015-01-08 | 2016-07-14 | Biontech Ag | Agonistic tnf receptor binding agents |
WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
WO2016120789A1 (en) * | 2015-01-28 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Agonistic icos binding proteins |
Non-Patent Citations (56)
Title |
---|
"Remington's Pharmaceutical Sciences", 1980 |
ANDERSON ET AL., PROC NATL ACAD SCI USA, vol. 101, no. 2, 2004, pages 7566 - 7571 |
ATWELL ET AL., J. MOL. BIOL., vol. 270, 1997, pages 26 |
BACA ET AL., J. BIOL. CHEM., vol. 272, no. 16, 1997, pages 10678 - 10684 |
CARPENTER ERICA L ET AL: "Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 7, 93, 11 November 2009 (2009-11-11), pages 1 - 10, XP021063609, ISSN: 1479-5876, DOI: 10.1186/1479-5876-7-93 * |
CARTER ET AL., PROC NATL ACAD SCI USA, vol. 89, 1992, pages 4285 - 4289 |
CHIN ET AL., SCIENCE, vol. 301, no. 5635, 2003, pages 964 - 967 |
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CROPP; SHULTZ, TRENDS GENET., vol. 20, no. 12, 2004, pages 625 - 630 |
DALL' ACQUA ET AL., J. IMMUNOL., vol. 169, 2002, pages 5171 - 5180 |
DAVIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 190, 2002, pages 123 - 136 |
DE PASCALIS ET AL., J. IMMUNOL., vol. 169, 2002, pages 3076 - 3084 |
EDELMAN ET AL., PROC NATL ACAD SCI USA, vol. 63, 1969, pages 78 - 85 |
FOS ET AL., J. IMMUNOL., 2008, pages 1969 - 1977 |
GHETIE; WARD, IMMUNOL TODAY, vol. 18, no. 12, 1997, pages 592 - 598 |
GILBOA ELI ET AL: "Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors", CLINICAL CANCER RESEARCH, vol. 19, no. 5, March 2013 (2013-03-01), pages 1054 - 1062, XP002775237 * |
GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4181 - 4185 |
GROS, J. CLINICAL INVEST., vol. 124, no. 5, 2014, pages 2246 |
GUNASEKARAN ET AL., J. BIOL. CHEM., vol. 285, no. 25, 2010, pages 19637 |
HE ET AL., J. IMMUNOL., vol. 160, 1998, pages 1029 - 1035 |
IGAWA ET AL., PEDS, vol. 23, no. 5, 2010, pages 385 - 392 |
J. W. CHIN ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, 2002, pages 9026 - 9027 |
J. W. CHIN ET AL., PICAS UNITED STATES OF AMERICA, vol. 99, 2002, pages 11020 - 11024 |
J. W. CHIN; P. G. SCHULTZ, CHEMBIOCHEM, vol. 11, 2002, pages 1135 - 1137 |
JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
JONES, NATURE, vol. 321, 1986, pages 522 - 525 |
KABAT ET AL.: "SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest. 5th ed.", 1991, UNITED STATES PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH |
KRAUSS ET AL., PROTEIN ENGINEERING, vol. 16, no. 10, 2003, pages 753 - 759 |
L. WANG; P. G. SCHULTZ, CHEM., 2002, pages 1 - 10 |
LABRIJN, PNAS, vol. 110, no. 13, 2013, pages 5145 - 5150 |
LAFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, no. 1, 2003, pages 55 - 77 |
LEWIS ET AL., NAT BIOTECHNOL, vol. 32, no. 2, 2014, pages 191 - 198 |
MADRENAS JOAQUÍN ET AL: "Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand.", JOURNAL OF IMMUNOLOGY, vol. 172, no. 10, 15 May 2004 (2004-05-15), (BALTIMORE, MD. : 1950), pages 5948 - 5956, XP002775234, ISSN: 0022-1767, DOI: 10.4049/jimmunol.172.10.5948 * |
MERCHANT ET AL., NATURE BIOTECH., vol. 16, 1998, pages 677 |
MERCHANT ET AL., PNAS, 23 July 2013 (2013-07-23), pages E2987 - E2996 |
MERCHANT, NAT BIOTECHNOL, vol. 16, no. 7, 1998, pages 677 - 81 |
O'CONNOR ET AL., PROTEIN ENG, vol. 11, 1998, pages 321 - 328 |
PRESTA ET AL., CANCER RES., vol. 57, no. 20, 1997, pages 4593 - 4599 |
QUEEN ET AL., PROC NATL ACAD SCI, USA, vol. 86, 1989, pages 10029 - 10033 |
RADER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 8910 - 8915 |
RIDGWAY ET AL., PROTEIN ENGINEERING, vol. 9, no. 7, 1996, pages 617 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329 |
ROGUSKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 969 - 973 |
ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654 |
ROSOK ET AL., J. BIOL. CHEM., vol. 271, no. 37, 1996, pages 22611 - 22618 |
SIMON ET AL., PNAS USA, vol. 89, no. 20, 1992, pages 9367 |
STROP ET AL., J MOL BIOL, vol. 420, no. 3, 2012, pages 204 - 219 |
TAN ET AL., J. IMMUNOL., vol. 169, 2002, pages 1119 - 1125 |
TSURUSHITA; VASQUEZ: "Molecular Biology of B Cells", 2004, ELSEVIER SCIENCE, article "Humanization of Monoclonal Antibodies", pages: 533 - 545 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536 |
WHITLOW ET AL., PROTEIN ENGINEERING, vol. 6, no. 8, 1993, pages 989 - 995 |
WU ET AL., J. MOL. BIOL., vol. 294, 1999, pages 151 - 162 |
XIAOZHOU FAN ET AL: "Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 211, no. 4, 31 March 2014 (2014-03-31), US, pages 715 - 725, XP055414943, ISSN: 0022-1007, DOI: 10.1084/jem.20130590 * |
YOKOSUKA TADASHI ET AL: "Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation.", IMMUNITY, vol. 33, no. 3, 24 September 2010 (2010-09-24), pages 326 - 339, XP002775235, ISSN: 1097-4180, DOI: 10.1016/j.immuni.2010.09.006 * |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11773175B2 (en) | 2014-03-04 | 2023-10-03 | Kymab Limited | Antibodies, uses and methods |
US11753479B2 (en) | 2014-03-04 | 2023-09-12 | Kymab Limited | Nucleic acids encoding anti-OX40L antibodies |
US11965026B2 (en) | 2016-06-20 | 2024-04-23 | Kymab Limited | Anti-PD-L1 and IL-2 cytokines |
US10604576B2 (en) | 2016-06-20 | 2020-03-31 | Kymab Limited | Antibodies and immunocytokines |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
US11685786B2 (en) | 2016-09-23 | 2023-06-27 | Merus N.V. | Binding molecules that bind CD137 and PD-L1 |
US10882908B2 (en) | 2016-10-11 | 2021-01-05 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
US10844119B2 (en) | 2016-10-11 | 2020-11-24 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
US11993651B2 (en) | 2016-10-11 | 2024-05-28 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11098117B2 (en) | 2017-04-13 | 2021-08-24 | Agenus Inc. | Anti-CD137 antibodies and methods of use thereof |
US11242385B2 (en) | 2017-04-13 | 2022-02-08 | Agenus Inc. | Anti-CD137 antibodies and methods of use thereof |
US11440960B2 (en) | 2017-06-20 | 2022-09-13 | Kymab Limited | TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo |
WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
JP2021521779A (en) * | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | A heterodimer fusion protein targeting LAG-3, including the IL-15 / IL-15RA Fc fusion protein and the LAG-3 antigen binding domain. |
JP7366056B2 (en) | 2018-04-18 | 2023-10-20 | ゼンコア インコーポレイテッド | A heterodimeric fusion protein targeting LAG-3, comprising an IL-15/IL-15RA Fc fusion protein and a LAG-3 antigen binding domain |
JP2021524282A (en) * | 2018-05-17 | 2021-09-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Receptor inhibition by phosphatase mobilization |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
WO2020010284A1 (en) * | 2018-07-04 | 2020-01-09 | Cytoimmune Therapeutics, LLC | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 |
WO2020018354A1 (en) | 2018-07-19 | 2020-01-23 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
CN112334488B (en) * | 2018-07-19 | 2023-12-08 | 伊莱利利公司 | Bispecific antibodies targeting immune checkpoints |
CN112334488A (en) * | 2018-07-19 | 2021-02-05 | 伊莱利利公司 | Bispecific antibodies targeting immune checkpoints |
JP2021530506A (en) * | 2018-07-19 | 2021-11-11 | イーライ リリー アンド カンパニー | Bispecific antibodies targeting immune checkpoints |
JP7090204B2 (en) | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | Bispecific antibodies targeting immune checkpoints |
US11939381B2 (en) | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
CN110964114A (en) * | 2018-09-29 | 2020-04-07 | 上海博槿生物科技有限公司 | Double-target antigen binding molecule |
CN110964114B (en) * | 2018-09-29 | 2023-07-04 | 上海博槿生物科技有限公司 | Double-target antigen binding molecule |
CN113166250A (en) * | 2018-11-30 | 2021-07-23 | Abl生物公司 | Anti-4-1 BB antibodies and uses thereof |
CN113166250B (en) * | 2018-11-30 | 2023-10-03 | Abl生物公司 | Anti-4-1 BB antibodies and uses thereof |
JP2022513694A (en) * | 2018-11-30 | 2022-02-09 | エービーエル バイオ インコーポレイテッド | Anti-PD-L1 / anti-4-1BB bispecific antibody and its use |
EP3887403A4 (en) * | 2018-11-30 | 2022-08-31 | ABL Bio Inc. | Anti-4-1bb antibody and use thereof |
JP7328658B2 (en) | 2018-11-30 | 2023-08-17 | エービーエル バイオ インコーポレイテッド | Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof |
WO2020107715A1 (en) * | 2018-11-30 | 2020-06-04 | Abl Bio Inc. | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
CN114249818A (en) * | 2018-12-31 | 2022-03-29 | 美勒斯公司 | Truncated multivalent multimers |
WO2020141974A1 (en) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021030488A1 (en) * | 2019-08-12 | 2021-02-18 | Bienvenue David Leonard | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
WO2021046289A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab |
WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
EP4041772A4 (en) * | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co Ltd | Antibodies binding 4-1bb and uses thereof |
WO2021091953A1 (en) * | 2019-11-05 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | N-terminal scfv multispecific binding molecules |
WO2021110935A1 (en) * | 2019-12-06 | 2021-06-10 | Oncoone Research & Development Gmbh | Anti-oxMIF/anti-CD3 BISPECIFIC ANTIBODY CONSTRUCTS |
US11773176B2 (en) | 2020-01-24 | 2023-10-03 | Aprilbio Co., Ltd. | Multispecific antibodies, compositions comprising the same, and vectors and uses thereof |
WO2021209358A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein |
WO2021209357A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
WO2021209356A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
US20220153869A1 (en) * | 2020-11-16 | 2022-05-19 | Tavotek Biotherapeutics (Hong Kong) Limited | Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof |
WO2022140701A1 (en) | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains |
US20220227867A1 (en) * | 2020-12-24 | 2022-07-21 | Xencor, Inc. | ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS |
WO2023001987A2 (en) | 2021-07-22 | 2023-01-26 | University Of Dundee | Therapeutic muteins |
WO2023064927A1 (en) * | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023064929A1 (en) * | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023109900A1 (en) * | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210095030A1 (en) | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors | |
US20240026002A1 (en) | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors | |
US11492407B2 (en) | Bispecific checkpoint inhibitor antibodies | |
WO2018045110A1 (en) | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors | |
CA3029328A1 (en) | Heterodimeric antibodies that bind somatostatin receptor 2 | |
AU2016365742A1 (en) | Heterodimeric antibodies that bind CD3 and PSMA | |
US20210253736A1 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
WO2020180726A1 (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
JP2022111148A (en) | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors | |
EP4149632A1 (en) | Heterodimeric antibodies that bind msln and cd3 | |
JP2019529368A5 (en) | ||
RU2788521C2 (en) | Bispecific immunomodulatory antibodies that bind costimulatory receptors and checkpoint receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17765002 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019511464 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3035343 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197009280 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017321625 Country of ref document: AU Date of ref document: 20170830 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017765002 Country of ref document: EP Effective date: 20190401 |